<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523421001823</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113333</dc:identifier><eid>1-s2.0-S0223523421001823</eid><prism:doi>10.1016/j.ejmech.2021.113333</prism:doi><pii>S0223-5234(21)00182-3</pii><dc:title>Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>216</prism:volume><prism:startingPage>113333</prism:startingpage><prism:pageRange>113333</prism:pagerange><articleNumber>113333</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-04-15</prism:coverdate><prism:coverDisplayDate>15 April 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Gao, Dingding</dc:creator><dc:creator>Jin, Nan</dc:creator><dc:creator>Fu, Yixian</dc:creator><dc:creator>Zhu, Yueyue</dc:creator><dc:creator>Wang, Yujie</dc:creator><dc:creator>Wang, Ting</dc:creator><dc:creator>Chen, Yuehong</dc:creator><dc:creator>Zhang, Mingming</dc:creator><dc:creator>Xiao, Qiang</dc:creator><dc:creator>Huang, Min</dc:creator><dc:creator>Li, Yingxia</dc:creator><dc:description>
                  The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer. The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment. In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compound 16w, a series of benzothiazole derivatives with unique binding mode in SH2 domain of STAT3 were designed, synthesized and biologically evaluated. Of note, compound B19 demonstrated excellent activity against IL-6/STAT3 signaling pathway with the IC50 value as low as 0.067 μM as determined by a luciferase reporter assay. Moreover, multiple compounds displayed potent antiproliferative activity against MDA-MB-468 and JAK2 mutant HEL cell lines. Further biochemical study using Western blot assay indicated that B19 blocked the phosphorylation of STAT3 at Tyr 705 and Ser 727 and thus suppressed STAT3-mediated gene expression of c-MYC and MCL-1. Simultaneously, it induced cancer cell G2/M phase arrest and apoptosis both in MDA-MB-468 and HEL cell lines. Finally, molecular docking study along with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays disclosed the binding mode of B19 in STAT3 SH2 domain. Taken together, our finding suggests that B19 is a promising therapeutic STAT3 inhibitor for cancer treatment.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>STAT3 signaling pathway</dcterms:subject><dcterms:subject>Benzothiazole</dcterms:subject><dcterms:subject>Rational design</dcterms:subject><dcterms:subject>Antitumor activity</dcterms:subject><dcterms:subject>Molecular docking</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523421001823" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523421001823" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="164" size="29917">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="642" height="357" size="101745">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="46" height="30" size="1058">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="212" height="76" size="4827">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="25" height="19" size="607">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="301" size="77196">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="416" height="99" size="10797">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="233" size="30352">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="179" size="31965">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="32" height="20" size="670">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="106" size="19511">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="253" size="28326">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="223" size="38896">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="sc6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="185" size="23738">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="46" height="24" size="792">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="26" size="961">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="335" size="66428">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="39" height="20" size="664">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="39" height="13" size="702">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="46" height="30" size="1067">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="277" size="37327">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="45" height="20" size="819">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="283" size="52897">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="558" height="460" size="63043">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="182" height="78" size="5378">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="58" size="4215">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="18970">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="136" size="2421">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="78" size="2410">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="115" height="88" size="1587">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="102" size="12852">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="52" size="2276">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="3961">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="4111">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="144" height="89" size="1741">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="47" size="3676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="sc5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="86" size="4145">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc5.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="8811">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="sc6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="63" size="3465">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc6.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="205" height="105" size="2282">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="2772">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="7697">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="175" height="88" size="2025">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="175" height="57" size="1895">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="136" size="3205">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="sc4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="94" size="4769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc4.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="201" height="88" size="2450">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="90" size="5928">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="9143">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="94" size="3360">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="728" size="214206">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2844" height="1580" size="886640">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="207" height="136" size="6309">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="939" height="335" size="33039">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="88" size="2405">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2862" height="1334" size="627461">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1844" height="440" size="78879">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2862" height="1032" size="235508">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3060" height="794" size="219661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="144" height="89" size="2881">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="471" size="135535">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2862" height="1120" size="221198">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2666" height="986" size="332343">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2862" height="820" size="184105">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="205" height="105" size="3681">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="230" height="115" size="5032">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3060" height="1484" size="452607">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="175" height="88" size="3368">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="175" height="57" size="3125">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="207" height="136" size="6047">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2862" height="1226" size="285335">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="201" height="88" size="3960">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3060" height="1252" size="387967">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2470" height="2037" size="504023">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="807" height="345" size="37210">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="10021502">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1008348">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001823-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85102075708</scopus-id><scopus-eid>2-s2.0-85102075708</scopus-eid><pubmed-id>33689932</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85102075708" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210302">2021-03-02</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210302">2021-03-02</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210306">2021-03-06</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210306">2021-03-06</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-04-07T08:42:37</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523421001823</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00182-3</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523421001823</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113333</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00050</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210504">2021-05-04T11:48:20.33089Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210415</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1614704180">2021-03-02T16:56:20.277785Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>216</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>216</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 216</xocs:vol-iss-suppl-text>
      <xocs:sort-order>28</xocs:sort-order>
      <xocs:first-fp>113333</xocs:first-fp>
      <xocs:article-number>113333</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113333</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20210415</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 April 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-04-15</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>RATIONALDRUGDESIGNBENZOTHIAZOLEBASEDDERIVATIVESPOTENTSIGNALTRANSDUCERACTIVATORTRANSCRIPTION3STAT3SIGNALINGPATHWAYINHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>GAO</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>D</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological assays</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Inhibitory activity on STAT3 transcription</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro cell growth inhibitory activity</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro kinases activity test</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The selectivity against related IFN-γ/STAT1 and TNF-α/NF-κB signaling pathways</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Apoptosis induction and G2/M cell-cycle arrest in MDA-MB-468 and HEL cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>SPR assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fluorescence polarization (FP) assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular docking study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B1</ce:bold>–<ce:bold>B14</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)Benzo[d]thiazol-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide</ce:italic> (<ce:bold>B1</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Methoxy-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] <ce:italic>thiazol-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide (</ce:italic>
                        <ce:bold>B2</ce:bold>
                        <ce:italic>)</ce:italic>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Fluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B3</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Chloro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol<ce:italic>-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide (</ce:italic>
                        <ce:bold>B4</ce:bold>
                        <ce:italic>)</ce:italic>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Bromo-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B5</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Cyano-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B6</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Ethyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B7</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-<ce:italic>(pentan-2-yloxy)-3-propylbenzamide (</ce:italic>
                        <ce:bold>B8</ce:bold>
                        <ce:italic>)</ce:italic>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4- <ce:italic>(pentan-2-yloxy)-3-(trifluoromethyl)benzamide (</ce:italic>
                        <ce:bold>B9</ce:bold>
                        <ce:italic>)</ce:italic>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B10</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.11</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Methoxy-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B11</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.12</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Fluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B12</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.13</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Chloro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B13</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.14</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2,3-Difluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B14</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of <ce:bold>B15</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Methyl (R)-3-methyl-4-(pentan-2-yloxy)benzoate (<ce:bold>8a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(R)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(R)-3-methyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>10a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-(((R)-pentan-2-yl)oxy)benzamide (<ce:bold>B15</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of <ce:bold>B16</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Methyl (S)-3-methyl-4-(pentan-2-yloxy)benzoate (<ce:bold>8b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>10b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(((R)-pentan-2-yl)oxy)benzamide (<ce:bold>B16</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthesis of <ce:bold>B17</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2,3-Dimethyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2,3-Dimethyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>10c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2,3-Dimethyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B17</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B18–B26</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2, 4-dihydroxy-3-methylbenzaldehyde (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of compounds <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.2.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Hydroxy-3-methyl-4-(pentan-2-yloxy) benzaldehyde (<ce:bold>17a</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.2.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Hydroxy-4-isobutoxy-3-methylbenzaldehyde (<ce:bold>17b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.2.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>4-Isopropoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>17c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of compounds <ce:bold>18a</ce:bold>-<ce:bold>18d</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.3.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Methoxy-3-methyl-4-(pentan-2-yloxy) benzaldehyde (<ce:bold>18a</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.3.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>4-Isobutoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>18b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.3.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>4-Isopropoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>18c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.3.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2,4-Dimethoxy-3-methylbenzaldehyde (<ce:bold>18d</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of compounds <ce:bold>19a</ce:bold>-<ce:bold>19d</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.4.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Methoxy-3-methyl-4-(pentan-2-yloxy) benzoic acid (<ce:bold>19a</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.4.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>4-Isobutoxy-2-methoxy-3-methylbenzoic acid (<ce:bold>19b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.4.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>4-Isopropoxy-2-methoxy-3-methylbenzoic acid (<ce:bold>19c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.4.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2,4-Dimethoxy-3-methylbenzoic acid (<ce:bold>19d</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>20a</ce:bold>-<ce:bold>20d</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>12b</ce:bold>-<ce:bold>12d</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.6.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(4-methoxyphenyl)ethyl)acetamide (<ce:bold>12b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.6.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(3-methoxyphenyl)ethyl)acetamide (<ce:bold>12c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.6.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(2-methoxyphenyl)ethyl)acetamide (<ce:bold>12d</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>13b</ce:bold>-<ce:bold>13d</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.7.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(4-hydroxyphenyl)ethyl)acetamide (<ce:bold>13b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.7.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(3-hydroxyphenyl)ethyl)acetamide (<ce:bold>13c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.7.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2-chloro-N-(1-(2-hydroxyphenyl)ethyl)acetamide (<ce:bold>13d</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>14a</ce:bold>-<ce:bold>14e</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Methoxy-3-methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B18</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Methoxy-N-(2-((2-(((S)-1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo [d]thiazol-6-yl)-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B19</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>2-Methoxy-N-(2-((2-(((S)-1-(3-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B20</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>N-(2-((2-(((S)-1-(4-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B21</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.5</xocs:item-toc-label>
                        <xocs:item-toc-section-title>N-(2-((2-(((S)-1-(3-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B22</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.6</xocs:item-toc-label>
                        <xocs:item-toc-section-title>N-(2-((2-(((S)-1-(2-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B23</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.7</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-4-isobutoxy-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2- oxoethyl)thio) benzo [d]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B24</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.8</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-4-isopropoxy-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)- 2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B25</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.5.9.9</xocs:item-toc-label>
                        <xocs:item-toc-section-title>(S)-2,4-dimethoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B26</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-(benzyloxy)-2-hydroxy-3-methylbenzaldehyde (<ce:bold>22</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-(benzyloxy)-2-methoxy-3-methylbenzaldehyde (<ce:bold>23</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-(benzyloxy)-2-methoxy-3-methylbenzoic acid (<ce:bold>24</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-Hydroxy-2-methoxy-3-methylbenzoic acid (<ce:bold>25</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Methyl 4-hydroxy-2-methoxy-3-methylbenzoate (<ce:bold>26</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>27a</ce:bold>-<ce:bold>27d</ce:bold>
                     </xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.6.6.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>Methyl 2-methoxy-4-(2-methoxyethoxy)-3-methylbenzoate (<ce:bold>27a</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.6.6.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>Methyl 2-methoxy-3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)benzoate (<ce:bold>27b</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.6.6.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>Methyl 4-(2-(dimethylamino)ethoxy)-2-methoxy-3-methylbenzoate (<ce:bold>27c</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.6.6.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>Methyl 2-methoxy-3-methyl-4-(2-morpholinoethoxy)benzoate (<ce:bold>27d</ce:bold>)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Methoxy-4-(2-methoxyethoxy)-3-methylbenzoic acid (<ce:bold>28a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>28b</ce:bold>-<ce:bold>28d</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>29a</ce:bold>-<ce:bold>29d</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.10.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2-methoxy-4-(2-methoxyethoxy)-N-(2-((2-((1-(4-methoxyphenyl)ethyl) amino)-2-oxoethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B27</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.10.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)benzamide (<ce:bold>B28</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.10.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-4-(2-(dimethylamino)ethoxy)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl) ethyl)amino)-2-oxoethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B29</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.10.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(2-morpholinoethoxy)benzamide (<ce:bold>B30</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B31</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Tert-butyl (S)-(2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)carbamate (<ce:bold>31</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2-amino-N-(1-(4-methoxyphenyl)ethyl)acetamide (<ce:bold>32</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)–N-(1-(4-methoxyphenyl)ethyl)-2-((6-nitrobenzo[<ce:italic>d</ce:italic>]thiazol-2-yl)amino) acetamide (<ce:bold>33</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2-((6-aminobenzo[<ce:italic>d</ce:italic>]thiazol-2-yl)amino)-N-(1-(4-methoxyphenyl)ethyl) acetamide (<ce:bold>34</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.7.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2,4-dimethoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) amino)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B31</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of <ce:bold>B32</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(2-chlorobenzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-2,4-dimethoxy-3-methylbenzamide (<ce:bold>36</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(2-chlorobenzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-2,4-dimethoxy-3-methylbenzamide (<ce:bold>37</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-((6-(2,4-dimethoxy-3-methylbenzamido)benzo[<ce:italic>d</ce:italic>]thiazol-2-yl)oxy)acetic acid (<ce:bold>38</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(S)-2,4-dimethoxy-N-(2-(2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethoxy) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B32</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Luciferase report assay</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.2.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Cell lines culture</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.2.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Luciferase report assay</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell viability assays</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.2.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Cell lines culture</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.2.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>MTT assay</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blotting</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro kinases activities test</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Flow cytometry analysis of apoptotic cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle effect</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Surface plasmon resonance analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fluorescence polarization assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular docking</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgement</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>BOWMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>JAMES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1630</xocs:ref-first-fp>
            <xocs:ref-last-lp>1635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>IHLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>369</xocs:ref-first-fp>
            <xocs:ref-last-lp>398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>16975</xocs:ref-first-fp>
            <xocs:ref-last-lp>16980</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>45443</xocs:ref-first-fp>
            <xocs:ref-last-lp>45455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>ALEXANDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>410</xocs:ref-first-fp>
            <xocs:ref-last-lp>416</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>KUBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1169</xocs:ref-first-fp>
            <xocs:ref-last-lp>1176</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>SHUAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>593</xocs:ref-first-fp>
            <xocs:ref-last-lp>605</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>BUETTNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>945</xocs:ref-first-fp>
            <xocs:ref-last-lp>954</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>6613</xocs:ref-first-fp>
            <xocs:ref-last-lp>6626</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>409</xocs:ref-first-fp>
            <xocs:ref-last-lp>422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>HERRMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>7455</xocs:ref-first-fp>
            <xocs:ref-last-lp>7464</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>KORTYLEWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>228</xocs:ref-first-fp>
            <xocs:ref-last-lp>233</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KORTYLEWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1314</xocs:ref-first-fp>
            <xocs:ref-last-lp>1321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>KUMARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>11553</xocs:ref-first-fp>
            <xocs:ref-last-lp>11572</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>GHARIBI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>173107</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>YOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>729</xocs:ref-first-fp>
            <xocs:ref-last-lp>739</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>COLEMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>6661</xocs:ref-first-fp>
            <xocs:ref-last-lp>6670</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>GELAIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5165</xocs:ref-first-fp>
            <xocs:ref-last-lp>5206</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib29a">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1839</xocs:ref-first-fp>
            <xocs:ref-last-lp>1844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib29b">
            <xocs:ref-normalized-surname>JONKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>263</xocs:ref-first-fp>
            <xocs:ref-last-lp>270</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>YOO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>510</xocs:ref-first-fp>
            <xocs:ref-last-lp>518</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib31a">
            <xocs:ref-normalized-surname>DI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>846</xocs:ref-first-fp>
            <xocs:ref-last-lp>853</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib31ab"/></xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>301</xocs:ref-first-fp>
            <xocs:ref-last-lp>310</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>TEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>6593</xocs:ref-first-fp>
            <xocs:ref-last-lp>6598</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>NIELSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>4819</xocs:ref-first-fp>
            <xocs:ref-last-lp>4832</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>MOREAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2305</xocs:ref-first-fp>
            <xocs:ref-last-lp>2309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>GUAGNANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7066</xocs:ref-first-fp>
            <xocs:ref-last-lp>7083</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>4451</xocs:ref-first-fp>
            <xocs:ref-last-lp>4454</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>EOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1720</xocs:ref-first-fp>
            <xocs:ref-last-lp>1723</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5579</xocs:ref-first-fp>
            <xocs:ref-last-lp>5601</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>BISHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5965</xocs:ref-first-fp>
            <xocs:ref-last-lp>5978</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>BAMBOROUGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>552</xocs:ref-first-fp>
            <xocs:ref-last-lp>557</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>BHARADWAJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1341</xocs:ref-first-fp>
            <xocs:ref-last-lp>1353</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>DECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2628</xocs:ref-first-fp>
            <xocs:ref-last-lp>2637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>KIUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>63</xocs:ref-first-fp>
            <xocs:ref-last-lp>73</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>PUTHIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>3945</xocs:ref-first-fp>
            <xocs:ref-last-lp>3950</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>114</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>FENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112428</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1088</xocs:ref-first-fp>
            <xocs:ref-last-lp>1091</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>869</xocs:ref-first-fp>
            <xocs:ref-last-lp>873</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>SAITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>464</xocs:ref-first-fp>
            <xocs:ref-last-lp>471</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>GAOX2021X113333</xocs:refkey3>
         <xocs:refkey4ai>GAOX2021X113333XD</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-03-06T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-03-06T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-02-28T09:28:59.681Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00182-3</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523421001823</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523421001823</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113333</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-05-04T11:48:20.33089Z</xocs:timestamp>
         <xocs:cover-date-start>2021-04-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/MAIN/application/pdf/fe13f782c28c4f1d99996dd31e4edd89/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>3238153</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>20</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523421001823-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/PREVIEW/image/png/d01bbe3c8943a47eb2f5faf2053a3e98/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>60428</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc1/DOWNSAMPLED/image/jpeg/101f4253c009150f61b2ab8f26852cee/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29917</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr6/DOWNSAMPLED/image/jpeg/a6f7b3da8ba472e6ea759c394077c9f9/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>101745</xocs:filesize>
               <xocs:pixel-height>357</xocs:pixel-height>
               <xocs:pixel-width>642</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx5/DOWNSAMPLED/image/jpeg/1a33be6c9121f2fdd01704c382bf1c4f/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1058</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>46</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx2/DOWNSAMPLED/image/jpeg/0ea4fcb894f290e17f3567617d25fa44/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4827</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>212</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx9/DOWNSAMPLED/image/jpeg/23f357bb1118c01f9ef96c7ded56970d/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>607</xocs:filesize>
               <xocs:pixel-height>19</xocs:pixel-height>
               <xocs:pixel-width>25</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr2/DOWNSAMPLED/image/jpeg/4db94c5deb3b5e28990a5997596268e3/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>77196</xocs:filesize>
               <xocs:pixel-height>301</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx3/DOWNSAMPLED/image/jpeg/e632bbc54de6da43e31ee5db425eeab6/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10797</xocs:filesize>
               <xocs:pixel-height>99</xocs:pixel-height>
               <xocs:pixel-width>416</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr1/DOWNSAMPLED/image/jpeg/124150c7691fdf7e0dd8fea83cbeb503/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30352</xocs:filesize>
               <xocs:pixel-height>233</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc2/DOWNSAMPLED/image/jpeg/9f502c7a61a1601d1cc861d75b7b28d2/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31965</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx8/DOWNSAMPLED/image/jpeg/773282ae225f079a55aacae67b3f3121/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>670</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>32</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx1/DOWNSAMPLED/image/jpeg/c8069d072290475f4864fa6b5abdcf35/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19511</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc5/DOWNSAMPLED/image/jpeg/a9659d6fb1db4da820cfbe206b980476/sc5.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28326</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr3/DOWNSAMPLED/image/jpeg/945ccfe6475e36d4fa7fc504eb402dc0/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>38896</xocs:filesize>
               <xocs:pixel-height>223</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc6/DOWNSAMPLED/image/jpeg/76275f98b4d6e23ed2456de26c57c3cc/sc6.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc6</xocs:file-basename>
               <xocs:filename>sc6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23738</xocs:filesize>
               <xocs:pixel-height>185</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx4/DOWNSAMPLED/image/jpeg/1415b19586b30d65b6d0f4e1a684528b/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>792</xocs:filesize>
               <xocs:pixel-height>24</xocs:pixel-height>
               <xocs:pixel-width>46</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx13/DOWNSAMPLED/image/jpeg/3f52df1c4fdad57a8782ae8252426503/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>961</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr4/DOWNSAMPLED/image/jpeg/0a35859f9350cd76b7b1056100a11943/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66428</xocs:filesize>
               <xocs:pixel-height>335</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx12/DOWNSAMPLED/image/jpeg/cb84e91e3941585d725c1bff9edc6333/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>664</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>39</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx10/DOWNSAMPLED/image/jpeg/932bd30db08119697ea03cb91e1fb256/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>702</xocs:filesize>
               <xocs:pixel-height>13</xocs:pixel-height>
               <xocs:pixel-width>39</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx6/DOWNSAMPLED/image/jpeg/21d1041432ad4171fae87fe589d2cab9/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1067</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>46</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc4/DOWNSAMPLED/image/jpeg/7fdd577364b6b8fdc45f5febefd8fbff/sc4.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37327</xocs:filesize>
               <xocs:pixel-height>277</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx11/DOWNSAMPLED/image/jpeg/3f959444ba7966b5cc7425d464726275/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>819</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>45</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc3/DOWNSAMPLED/image/jpeg/98f322813a8e511748142997c9071656/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52897</xocs:filesize>
               <xocs:pixel-height>283</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr5/DOWNSAMPLED/image/jpeg/de49d96d569850bfbc81a10b7b59c518/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63043</xocs:filesize>
               <xocs:pixel-height>460</xocs:pixel-height>
               <xocs:pixel-width>558</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx7/DOWNSAMPLED/image/jpeg/8e52f2ff6a99cf821b3c7efd72f698d3/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5378</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc1/THUMBNAIL/image/gif/205bcab23a0cfebcbf8787c314563c61/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4215</xocs:filesize>
               <xocs:pixel-height>58</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr6/THUMBNAIL/image/gif/19f2bd2cf90907b05d01bafa7cae9878/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18970</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx5/THUMBNAIL/image/gif/ef0d96a313d0d1517b77f53049190815/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2421</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx2/THUMBNAIL/image/gif/63bda86deecd110d8681ab50cfed648c/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2410</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx9/THUMBNAIL/image/gif/84527cb1e7b9bdbf13c3c6d0efa93e49/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1587</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr2/THUMBNAIL/image/gif/7144b8a5ef452093f28027c35c130ee6/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12852</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx3/THUMBNAIL/image/gif/09791086a08c54edabe0d469ccbac738/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2276</xocs:filesize>
               <xocs:pixel-height>52</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr1/THUMBNAIL/image/gif/dbb4011beafe9def265d127ef98003f4/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3961</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc2/THUMBNAIL/image/gif/9968915ad26283905a7b1aa6b8d86d2c/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4111</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx8/THUMBNAIL/image/gif/37f611599bd3b767edd5066c0ef87c88/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1741</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>144</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx1/THUMBNAIL/image/gif/38a5178499679cc432e9f8a00fd7c5ee/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3676</xocs:filesize>
               <xocs:pixel-height>47</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc5/THUMBNAIL/image/gif/4270db08f3cee713e12ad0002a0d79b5/sc5.sml</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4145</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr3/THUMBNAIL/image/gif/8bf4b775a1a344e30d3a38b841f40eaf/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8811</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc6/THUMBNAIL/image/gif/ba77335feea2537b3fd99cc24ef5457f/sc6.sml</xocs:ucs-locator>
               <xocs:file-basename>sc6</xocs:file-basename>
               <xocs:filename>sc6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3465</xocs:filesize>
               <xocs:pixel-height>63</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx4/THUMBNAIL/image/gif/ac347f3cf4ecd22d7943dcea7fc6e94d/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2282</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>205</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx13/THUMBNAIL/image/gif/3e847c3ecc6c6eaca24371826fa4c221/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2772</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr4/THUMBNAIL/image/gif/e2bde5d83d1cde6c633bc96b72e0419c/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7697</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx12/THUMBNAIL/image/gif/5cf97ca6388becc7c99809970c8f818c/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2025</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx10/THUMBNAIL/image/gif/cf7d2305d5455b59afa675b1671332d1/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1895</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx6/THUMBNAIL/image/gif/d22ccfb3aa1ef73fd59814980ce6341c/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3205</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc4/THUMBNAIL/image/gif/3cc8f2c003c64db1d26fca432dacb275/sc4.sml</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4769</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx11/THUMBNAIL/image/gif/ef2befca52600ee73583eb27ab4a3d35/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2450</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>201</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc3/THUMBNAIL/image/gif/3127bd7989274546ac3db97cc2edadc7/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5928</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr5/THUMBNAIL/image/gif/d8a7cd5a633673a9cc5e0fd759f1204c/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9143</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx7/THUMBNAIL/image/gif/6909a5f45671b73efb0452e9c39dda85/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3360</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc1/HIGHRES/image/jpeg/de8d5a036131da4bc703efb418a3d944/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>214206</xocs:filesize>
               <xocs:pixel-height>728</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr6/HIGHRES/image/jpeg/e80cc18d250accff795b2c9bf39487ac/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>886640</xocs:filesize>
               <xocs:pixel-height>1580</xocs:pixel-height>
               <xocs:pixel-width>2844</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx5/HIGHRES/image/jpeg/f139390668ea9aa4afa4830ce256f96e/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6309</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx2/HIGHRES/image/jpeg/564a15b8f112c5ed1baafa2d05d369da/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33039</xocs:filesize>
               <xocs:pixel-height>335</xocs:pixel-height>
               <xocs:pixel-width>939</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx9/HIGHRES/image/jpeg/b41e0f07646bef87b0f7c765bc5d54cf/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2405</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr2/HIGHRES/image/jpeg/3d0f6ef65a8678cccd39fcbd0525c5b2/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>627461</xocs:filesize>
               <xocs:pixel-height>1334</xocs:pixel-height>
               <xocs:pixel-width>2862</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx3/HIGHRES/image/jpeg/1b098d0f157373ce9b8cfbaa3db05bc2/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>78879</xocs:filesize>
               <xocs:pixel-height>440</xocs:pixel-height>
               <xocs:pixel-width>1844</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr1/HIGHRES/image/jpeg/19950f6f7009958003e39d59d6277db3/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>235508</xocs:filesize>
               <xocs:pixel-height>1032</xocs:pixel-height>
               <xocs:pixel-width>2862</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc2/HIGHRES/image/jpeg/b7eba186cb81b6d015fe7baf3924380b/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>219661</xocs:filesize>
               <xocs:pixel-height>794</xocs:pixel-height>
               <xocs:pixel-width>3060</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx8/HIGHRES/image/jpeg/80065dbeae9320dbbc03d23d3df4a7b1/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2881</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>144</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx1/HIGHRES/image/jpeg/6489752a0eaeada172d39a48054b0ae6/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>135535</xocs:filesize>
               <xocs:pixel-height>471</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc5/HIGHRES/image/jpeg/701fa12e5a456c9bd4e1577b3d64244a/sc5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>221198</xocs:filesize>
               <xocs:pixel-height>1120</xocs:pixel-height>
               <xocs:pixel-width>2862</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr3/HIGHRES/image/jpeg/b377e2a84838e8a5ad12e8f26db48606/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>332343</xocs:filesize>
               <xocs:pixel-height>986</xocs:pixel-height>
               <xocs:pixel-width>2666</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc6/HIGHRES/image/jpeg/0453a022a30cebabb632dab2ff53e2c2/sc6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc6</xocs:file-basename>
               <xocs:filename>sc6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>184105</xocs:filesize>
               <xocs:pixel-height>820</xocs:pixel-height>
               <xocs:pixel-width>2862</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx4/HIGHRES/image/jpeg/f5275113722725102019b2793c0add25/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3681</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>205</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx13/HIGHRES/image/jpeg/59fd1233ad042f44661df5fcb429f72d/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5032</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>230</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr4/HIGHRES/image/jpeg/6f184dfc98041255cb15a0146a3eced1/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>452607</xocs:filesize>
               <xocs:pixel-height>1484</xocs:pixel-height>
               <xocs:pixel-width>3060</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx12/HIGHRES/image/jpeg/9306d9927e233f34f96469eb39b297f9/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3368</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx10/HIGHRES/image/jpeg/ab6a369318fdca441becde39b60eebf9/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3125</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>175</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx6/HIGHRES/image/jpeg/b6dc6180592ee03ae0155a58a18fb309/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6047</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc4/HIGHRES/image/jpeg/604c12d0369397cb1574fcf7ee3423ba/sc4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>285335</xocs:filesize>
               <xocs:pixel-height>1226</xocs:pixel-height>
               <xocs:pixel-width>2862</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx11/HIGHRES/image/jpeg/2e5cdaff51bbb3791c55c90286e6aef4/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3960</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>201</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/sc3/HIGHRES/image/jpeg/a675e807e9e3eecaa4c272e22dbfbae2/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>387967</xocs:filesize>
               <xocs:pixel-height>1252</xocs:pixel-height>
               <xocs:pixel-width>3060</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/gr5/HIGHRES/image/jpeg/7b233d469b8ee032e22cf614d442544e/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>504023</xocs:filesize>
               <xocs:pixel-height>2037</xocs:pixel-height>
               <xocs:pixel-width>2470</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/fx7/HIGHRES/image/jpeg/800705a0e55abe7a7486bed653656beb/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37210</xocs:filesize>
               <xocs:pixel-height>345</xocs:pixel-height>
               <xocs:pixel-width>807</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001823/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/694d8b9300f86fd60e35d739d0379aaa/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>10021502</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001823-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1008348</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10DCPLL85X2/MAIN/application/pdf/75d20a505a4dab65913843e1b55dfecf/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113333</aid>
            <ce:article-number>113333</ce:article-number>
            <ce:pii>S0223-5234(21)00182-3</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113333</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Known representative STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523421001823/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">(A–B) Docking mode of hit compound <ce:bold>16w</ce:bold> with STAT3 SH2 domain (PDB <ce:inter-ref id="intref0035" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>), generated by Schrodinger, Maestro suite. Surface representation was created with PyMOL Viewer. (C) Rational design of target compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523421001823/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Western blot analysis of the inhibition of STAT3 phosphorylation at Tyr705 and Ser727, the downstream target proteins (c-Myc, MCL-1) by compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> in (A) HEL (<ce:italic>JAK2</ce:italic> V617F) and (B) MDA-MB-468 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523421001823/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Induction of apoptosis and cell-cycle arrest by compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> in MDA-MB-468 and HEL cells. (A) Effects of compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> on the induction of apoptosis. The cells were treated with increasing concentrations of the test compounds for 48 h and analyzed by annexin V/propidium iodide double staining. The data are representative of three independent experiments. ∗∗∗∗, p < 0.0001, ∗∗∗, p < 0.001, ∗∗, p < 0.01, ∗, p < 0.05. (B) Cell cycle analysis of compound <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> by flow cytometry. The cells were treated with increasing concentrations of test compounds for 48 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523421001823/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">SPR analysis of representative compounds with STAT3 SH2 domain. For <ce:bold>Sub</ce:bold>, compound concentrations were varied from 0.98 to 62.5 nM; for <ce:bold>Stattic</ce:bold>, compound concentrations were varied from 0.039 to 2.5 μM; For compound <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold>, a concentration range of 0.0485–6.25 μM was used. Time was measured in seconds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523421001823/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Molecular docking study of <ce:bold>B19</ce:bold> in STAT3 SH2 domain (PDB code: <ce:inter-ref id="intref0040" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>). (A) Chemical structure of compound <ce:bold>B19</ce:bold>. (B) Superimposed pose of <ce:bold>B19</ce:bold> (yellow) and pY705-Phe 710 peptide (green) bound in the surface of binding site. (C) Predicted hydrogen bonds interaction of <ce:bold>B19</ce:bold> (yellow) within STAT3 SH2 domain. (D) <ce:bold>B19</ce:bold> (yellow) bound in the surface of binding site. The figures were generated using Pymol.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523421001823/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Synthesis of compounds <ce:bold>B1</ce:bold>–<ce:bold>B14</ce:bold>. Reagents and conditions: (a) ClCH<ce:inf loc="post">2</ce:inf>COCl, Et<ce:inf loc="post">3</ce:inf>N, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 0 °C to rt; (b) 6-aminobenzothiazole-2-thiol, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, acetone, reflux; (c) 2-bromopentane, EtOH, KOH, reflux; (d) SOCl<ce:inf loc="post">2</ce:inf>, reflux; (e) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523421001823/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Synthesis of compounds <ce:bold>B15</ce:bold>–<ce:bold>B17</ce:bold>. Reagents and conditions: (a) <ce:bold>8a</ce:bold>: (<ce:italic>S</ce:italic>)-pentan-2-ol, triphenylphosphane, DEAD, THF, 0 °C to rt; <ce:bold>8b</ce:bold>: (<ce:italic>R</ce:italic>)-pentan-2-ol, triphenylphosphane, DEAD, THF, 0 °C to rt; <ce:bold>8c</ce:bold>: 2-bromopentane, EtOH, KOH, reflux; (b) 1 M NaOH (aq.), rt; (c) SOCl<ce:inf loc="post">2</ce:inf>, reflux; (d) <ce:bold>3</ce:bold>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523421001823/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Synthesis of compounds <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold>. Reagents and conditions: (a) 2-chloroacetyl chloride, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 0 °C to rt; (b) BBr<ce:inf loc="post">3</ce:inf> (17% in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>), CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 0 °C to rt; (c) 6-aminobenzothiazole-2-thiol, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, acetone, reflux; (d) POCl<ce:inf loc="post">3</ce:inf>, DMF, ethyl acetate, rt; (e) Bromoalkane, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, DMF, 80 °C; (f) CH<ce:inf loc="post">3</ce:inf>I, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, 40 °C; (g) NaClO<ce:inf loc="post">2</ce:inf>, NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>·2H<ce:inf loc="post">2</ce:inf>O, t-BuOH, rt; (h) SOCl<ce:inf loc="post">2</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, DMF, 0 °C to rt; (i) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S0223523421001823/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch4">
               <ce:label>Scheme 4</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Synthesis of compounds <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold>. Reagents and conditions: (a) Benzyl bromide, KI, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, acetonitrile, 80 °C; (b) CH<ce:inf loc="post">3</ce:inf>I, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, 40 °C; (c)NaClO<ce:inf loc="post">2</ce:inf>, NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>·2H<ce:inf loc="post">2</ce:inf>O, t-BuOH, rt; (d) Pd/C, H<ce:inf loc="post">2</ce:inf>, rt; (e) SO<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, CH<ce:inf loc="post">3</ce:inf>OH, rt; (f) Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, anhydrous DMF, 85 °C and 1-bromo-2-methoxyethane for <ce:bold>27a</ce:bold>, 1-(2-chloroethyl)pyrrolidine hydrochloride and KI for <ce:bold>27b,</ce:bold> 2-chloro-N,N-dimethylethan-1-amine hydrochloride and KI for <ce:bold>27c</ce:bold>, 4-(2-chloroethyl)morpholine hydrochloride and KI for <ce:bold>27d</ce:bold>; (g) 1 M NaOH (aq.), CH<ce:inf loc="post">3</ce:inf>OH, 50 °C, <ce:bold>28a</ce:bold>; 6 M HCl (aq.), 85 °C, <ce:bold>28b</ce:bold>-<ce:bold>28d</ce:bold>; (h) SOCl<ce:inf loc="post">2</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, DMF, rt; (i) <ce:bold>14a</ce:bold>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Scheme 4</ce:alt-text>
               <ce:link locator="sc4" xlink:href="pii:S0223523421001823/sc4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch5">
               <ce:label>Scheme 5</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Synthesis of compound <ce:bold>B31</ce:bold>. Reagents and conditions: (a) (<ce:italic>tert</ce:italic>-butoxycarbonyl)glycine, HATU, HoAt, DIPEA, THF, rt; (b) CF<ce:inf loc="post">3</ce:inf>COOH, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 0 °C; (c) 2-chloro-6-nitrobenzo [<ce:italic>d</ce:italic>]thiazole, n-Butanol, Et<ce:inf loc="post">3</ce:inf>N, reflux; (d) Fe powder, NH<ce:inf loc="post">4</ce:inf>Cl, EtOH/H<ce:inf loc="post">2</ce:inf>O, reflux; (e) <ce:bold>20d</ce:bold>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Scheme 5</ce:alt-text>
               <ce:link locator="sc5" xlink:href="pii:S0223523421001823/sc5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch6">
               <ce:label>Scheme 6</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Synthesis of compound <ce:bold>39</ce:bold>. Reagents and conditions: (a) <ce:bold>20d</ce:bold>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, r. t.; (b) Ethyl-2-hydroxyacetate, NaH, THF, 70 °C; (c) 1 M NaOH (aq.), CH<ce:inf loc="post">3</ce:inf>OH/THF, rt; (d) <ce:bold>11b</ce:bold>, HATU, HoAt, DIPEA, THF, rt.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Scheme 6</ce:alt-text>
               <ce:link locator="sc6" xlink:href="pii:S0223523421001823/sc6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0010" view="all">Inhibitory activity on STAT3 transcription as indicated by luciferase reporter gene assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Table 1</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523421001823/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="8">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">1</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">2</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IL-6/STAT3 pathway<cross-ref id="crosref0400" refid="tbl1fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0405" refid="tbl1fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">1</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">2</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IL-6/STAT3 pathway<cross-ref id="crosref0410" refid="tbl2fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0415" refid="tbl2fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.95 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.42 ± 0.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.72 ± 0.72</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.20 ± 0.27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.15 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.34 ± 0.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">C<inf loc="post">2</inf>H<inf loc="post">5</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>16w</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.60 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">B8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CH<inf loc="post">2</inf>CH<inf loc="post">2</inf>CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>LLL12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.098 ± 0.01</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">STAT3-dependent luciferase reporter gene assay in HepG2 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0020" view="all">The data are the mean ± SD from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0015" view="all">Inhibitory activity on STAT3 transcription as indicated by luciferase reporter gene assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx3" xlink:href="pii:S0223523421001823/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">2</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">3</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IL-6/STAT3 pathway<cross-ref id="crosref05f05" refid="tbl2fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref05e10" refid="tbl2fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.95 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523421001823/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.90 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523421001823/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.20 ± 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.46 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.16 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>LLL12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.098 ± 0.01</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0025" view="all">STAT3-dependent luciferase reporter gene assay in HepG2 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0030" view="all">The data are the mean ± SD from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0020" view="all">Inhibitory activity on STAT3 transcription as indicated by luciferase reporter gene assay.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0115" role="short">Table 3</ce:alt-text>
               <ce:link locator="fx7" xlink:href="pii:S0223523421001823/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">3</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">R<sup loc="post">4</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">X</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IL-6/STAT3 pathway<cross-ref id="crosref0420" refid="tbl3fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0425" refid="tbl3fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.16 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.067 ± 0.00</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.27 ± 0.00</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.20 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.15 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001823/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0145" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.17 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523421001823/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.20 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523421001823/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.22 ± 0.00</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.12 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523421001823/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.26 ± 0.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523421001823/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.03 ± 0.10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523421001823/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0170" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.52 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523421001823/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0175" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.24 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.49 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">O</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">8.86 ± 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>LLL12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.098 ± 0.01</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl3fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0035" view="all">STAT3-dependent luciferase reporter gene assay in HepG2 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0040" view="all">The data are the mean ± SD from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0025" view="all">Antiproliferative activity of the representative compounds against HEL (<ce:italic>JAK2</ce:italic> V617F) and MDA-MB-468 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0180" role="short">Table 4</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" role="rowgroup">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" role="rowgroup">HEL (<italic>JAK2</italic> V617F)<cross-ref id="crosref0430" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0440" refid="tbl4fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" role="rowgroup">MDA-MB-468<cross-ref id="crosref0435" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0445" refid="tbl4fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>16w</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.21 ± 0.20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.73 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.93 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.81 ± 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.41 ± 0.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.04 ± 0.27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.11 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.25 ± 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.87 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.50 ± 0.04</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.68 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.70 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.62 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.24 ± 0.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.97 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.59 ± 0.19</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.05 ± 1.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.02 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.29 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.81 ± 0.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.34 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">2.05 ± 0.23</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.44 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.16 ± 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">10.4 ± 1.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3.36 ± 0.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4.98 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">6.57 ± 0.64</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3.38 ± 1.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.77 ± 0.55</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>LLL12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.46 ± 0.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.73 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>Stattic</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.59 ± 0.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.92 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>INCB18424</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.40 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>AZD1480</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.73 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">5.87 ± 0.87</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0045" view="all">The inhibitory effects of these compounds on the proliferation of cancer cell lines were determined by the MTT assay.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0050" view="all">The data are the mean ± SD from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl5" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="tspara0030" view="all">Antiproliferative activity of <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> against MDA-MB-453 and MCF-7 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0185" role="short">Table 5</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" morerows="1" role="rowgroup">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">MDA-MB-453<cross-ref id="crosref0450" refid="tbl5fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">MCF-7<cross-ref id="crosref0455" refid="tbl5fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0460" refid="tbl5fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0465" refid="tbl5fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>Stattic</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4.40 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.70 ± 0.10</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl5fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0055" view="all">The inhibitory effects of these compounds on the proliferation of cancer cell lines were determined by the MTT assay.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl5fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0060" view="all">The data are the mean ± SD from at least two independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl6" rowsep="0">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="tspara0035" view="all">Inhibitory activities against a panel of representative kinases.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0190" role="short">Table 6</ce:alt-text>
               <tgroup cols="12">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <colspec colname="col12" colnum="12"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" morerows="1" role="rowgroup">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" nameend="col12" namest="col2" role="colgroup">Inhibition rate at 1.0 μM (%)<cross-ref id="crosref0470" refid="tbl6fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">VEGFR-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">PDGFR-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">EGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">ErbB2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">ErbB4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Abl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Eph-A2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IGF1R</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">−2.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">−0.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">−4.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">5.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">1.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">−6.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">9.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">4.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>INCB018424</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">80.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">91.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">78.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>Su11248</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">86.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">76.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>BIBW2992</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">98.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">93.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">88.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>Dasatinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>AEW541</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl6fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0065" view="all">The inhibition rates are the mean of three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl7" rowsep="0">
               <ce:label>Table 7</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="tspara0040" view="all">Inhibitory activity against related IFN-γ/STAT1 and TNF-α/NF-κB signaling pathways.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0195" role="short">Table 7</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IL-6/STAT3<cross-ref id="crosref0475" refid="tbl7fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0480" refid="tbl7fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">IFN-γ/STAT1<cross-ref id="crosref0485" refid="tbl7fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0490" refid="tbl7fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">TNF-α/NF-κB<cross-ref id="crosref0495" refid="tbl7fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                           <br/></br>IC<inf loc="post">50</inf>±SD (μM)<cross-ref id="crosref0500" refid="tbl7fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.16 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.35 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.067 ± 0.00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.32 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>BBI608</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.84 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">0.88 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">3.55 ± 0.21</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl7fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0070" view="all">STAT3-dependent luciferase reporter gene assay in HepG2 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl7fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0075" view="all">STAT1-dependent luciferase reporter gene assay in HepG2 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl7fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0080" view="all">NF-κB -dependent luciferase reporter gene assay in HEK-293 cell.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl7fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0085" view="all">The data are the mean ± SD from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl8" rowsep="0">
               <ce:label>Table 8</ce:label>
               <ce:caption id="cap0105">
                  <ce:simple-para id="tspara0045" view="all">FP-based competition binding assay of <ce:bold>B18, B19</ce:bold> and <ce:bold>Stattic.</ce:bold>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0200" role="short">Table 8</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" morerows="1" role="rowgroup">Compds.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center" nameend="col4" namest="col2" role="colgroup">Binding rate (%)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">100 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">50 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">20 μM</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>B19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center"><10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">
                           <bold>Stattic</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">95.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">71.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="center">62.3</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0050" view="all">
                     <ce:sup loc="post">a</ce:sup> The binding rates are the mean of three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:title id="title0010">Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523421001823-227fe214ecb13918ac46add9dc4fd2f3">
                  <ce:given-name>Dingding</ce:given-name>
                  <ce:surname>Gao</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0020" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523421001823-6ab809e3e4d074bec9c086f67396e35c">
                  <ce:given-name>Nan</ce:given-name>
                  <ce:surname>Jin</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0030" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523421001823-4ea74e7e623238c54fa6b68c211c132f">
                  <ce:given-name>Yixian</ce:given-name>
                  <ce:surname>Fu</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0040" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523421001823-a3a66c5954341c0baa826b462ff4c829">
                  <ce:given-name>Yueyue</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523421001823-0ef6d649b1ec00e55fdcddeeb9c9bc0e">
                  <ce:given-name>Yujie</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523421001823-23236c3674fb14e11afe6b20b621b585">
                  <ce:given-name>Ting</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523421001823-4ed015b292b84784b993c2f40b63213a">
                  <ce:given-name>Yuehong</ce:given-name>
                  <ce:surname>Chen</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523421001823-2003cf3b52f6207099659e44357193af">
                  <ce:given-name>Mingming</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523421001823-b34b4485ea1f99f87900547c8851ed5d">
                  <ce:given-name>Qiang</ce:given-name>
                  <ce:surname>Xiao</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523421001823-c73a5ff8f796f40fce939b4f8b1a5ee4">
                  <ce:given-name>Min</ce:given-name>
                  <ce:surname>Huang</ce:surname>
                  <ce:cross-ref id="crosref0075" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="aff4" id="crosref05fr15">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11" author-id="S0223523421001823-5b1ae97ae10a3f9b45062a904b84193b">
                  <ce:given-name>Yingxia</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0085" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523421001823-c93029cc9f8d6004d6ae8e69bf8195a3">
                  <ce:label>a</ce:label>
                  <ce:textfn>School of Pharmacy, Fudan University, Shanghai, 201203, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Fudan University</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">School of Pharmacy, Fudan University, Shanghai 201203, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523421001823-a3b76e026a24a8b3be77da544316890e">
                  <ce:label>b</ce:label>
                  <ce:textfn>Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Division of Antitumor Pharmacology</sa:organization>
                     <sa:organization>State Key Laboratory of Drug Research</sa:organization>
                     <sa:organization>Shanghai Institute of Materia Medica</sa:organization>
                     <sa:organization>Chinese Academy of Sciences</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523421001823-f9d6b6db0e3706c67f95ddfc335dc22c">
                  <ce:label>c</ce:label>
                  <ce:textfn>Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Innovation Research Institute of Traditional Chinese Medicine (IRI)</sa:organization>
                     <sa:organization>Shanghai University of Traditional Chinese Medicine</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S0223523421001823-211f68de21a03e3ac29ba11672433b3a">
                  <ce:label>d</ce:label>
                  <ce:textfn>University of Chinese Academy of Sciences, Beijing, 100049, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>University of Chinese Academy of Sciences</sa:organization>
                     <sa:city>Beijing</sa:city>
                     <sa:postal-code>100049</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">University of Chinese Academy of Sciences, Beijing 100049, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="8" month="12" year="2020"/></ce:date-received>
            <ce:date-revised day="19" month="2" year="2021"/></ce:date-revised>
            <ce:date-accepted day="20" month="2" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer. The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment. In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compound <ce:bold>16w</ce:bold>, a series of benzothiazole derivatives with unique binding mode in SH2 domain of STAT3 were designed, synthesized and biologically evaluated. Of note, compound <ce:bold>B19</ce:bold> demonstrated excellent activity against IL-6/STAT3 signaling pathway with the IC<ce:inf loc="post">50</ce:inf> value as low as 0.067 μM as determined by a luciferase reporter assay. Moreover, multiple compounds displayed potent antiproliferative activity against MDA-MB-468 and <ce:italic>JAK2</ce:italic> mutant HEL cell lines. Further biochemical study using Western blot assay indicated that <ce:bold>B19</ce:bold> blocked the phosphorylation of STAT3 at Tyr 705 and Ser 727 and thus suppressed STAT3-mediated gene expression of <ce:italic>c-MYC</ce:italic> and <ce:italic>MCL-1</ce:italic>. Simultaneously, it induced cancer cell G2/M phase arrest and apoptosis both in MDA-MB-468 and HEL cell lines. Finally, molecular docking study along with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays disclosed the binding mode of <ce:bold>B19</ce:bold> in STAT3 SH2 domain. Taken together, our finding suggests that <ce:bold>B19</ce:bold> is a promising therapeutic STAT3 inhibitor for cancer treatment.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523421001823/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>STAT3 signaling pathway</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Benzothiazole</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Rational design</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Antitumor activity</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Molecular docking</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Signal transducer and activator of transcription 3 (STAT3) is an intracellular latent transcription factor that belongs to STAT protein family [<ce:cross-ref id="crosref0095" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0100" refid="bib2">2</ce:cross-ref>]. It contains six functional domains including a dimerization domain at the N-terminus, a coiled-coil domain for protein-protein interactions, a central DNA-binding domain, a linker domain that affects DNA-binding stability, a classic Src homology 2 (SH2) domain and a carboxyl transactivation domain [<ce:cross-ref id="crosref0105" refid="bib2">2</ce:cross-ref>]. Generally, STAT3 transmits signals from the cell surface to the nucleus, as well as directly participates in transcriptional regulation of numerous gene expression [<ce:cross-ref id="crosref0110" refid="bib3">3</ce:cross-ref>,<ce:cross-ref id="crosref0115" refid="bib4">4</ce:cross-ref>]. Upon triggered by upstream signals, such as various cytokines and growth factors, the Janus kinases (JAKs) are recruited to the receptor and phosphorylate the tyrosine residues on the receptor, creating binding sites for proteins possessing SH2 domains, such as STAT3. The latter can bind to the receptor using SH2 domains and JAKs phosphorylate STAT3 at Tyrosine 705 (Tyr705), which causes STAT3 to dissociate from the receptor. Two activated STAT3 monomers undergo dimerization through reciprocal pTyr-SH2 domain interactions and then translocate into the nucleus to bind specific DNA sequence, leading to target gene transcription [<ce:cross-ref id="crosref0120" refid="bib5">5</ce:cross-ref>,<ce:cross-ref id="crosref0125" refid="bib6">6</ce:cross-ref>]. Under normal physiological conditions, the activation of STAT3 is rapid and transient due to the negative regulation by proteins such as protein inhibitor of activated STAT (PIAS) and suppressor of cytokine signaling (SOCS) [<ce:cross-refs id="crosrefs0010" refid="bib7 bib8 bib9">7–9</ce:cross-refs>]. Nevertheless, aberrant activation of STAT3 has a contributing role in diverse solid and hematological tumors as it is a point of intersection of multiple oncogenic signaling pathways [<ce:cross-refs id="crosrefs0015" refid="bib10 bib11 bib12 bib13 bib14">10–14</ce:cross-refs>]. Additionally, STAT3 plays a crucial role in immune cells and is being regarded as a potent immune checkpoint that mediates tumor-induced immunosuppression from various perspectives [<ce:cross-refs id="crosrefs0020" refid="bib15 bib16 bib17 bib18 bib19">15–19</ce:cross-refs>]. As STAT3 is the main mediator of IL-6 signaling pathway in Th17 cells, it also plays an important role in pathogenesis of autoimmune diseases, such as inflammatory bowel disease and rheumatoid arthritis [<ce:cross-ref id="crosref0130" refid="bib20">20</ce:cross-ref>,<ce:cross-ref id="crosref0135" refid="bib21">21</ce:cross-ref>]. Some other studies further showed that different subcellular localization patterns of STAT3 affected autophagy in various ways [<ce:cross-ref id="crosref0140" refid="bib22">22</ce:cross-ref>]. Therefore, the discovery of potent STAT3 inhibitors is of great significance for the treatment in many diseases, especially cancer [<ce:cross-ref id="crosref0145" refid="bib23">23</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">So far, a variety of STAT3 inhibitors containing peptide, peptidomimetic, small molecule and small-molecule degrader have been reported (<ce:cross-ref id="crosref0150" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) [<ce:cross-refs id="crosrefs0025" refid="bib24 bib25 bib26 bib27 bib28">24–28</ce:cross-refs>], which target the SH2 domain or DNA-binding domain to inhibit STAT3 transcriptional activity. However, there are only three small-molecule STAT3 inhibitors (BBI608, OPB-111077, C188-9) currently under investigation in clinical trials, perhaps due to the complexity of the biological functions of STAT3 signaling pathway or the poor physicochemical properties of STAT3 inhibitors. In detail, BBI608 (Napabucasin), a direct STAT3 inhibitor that blocks stem cell activity in cancer cells, is the only STAT3-targeted agent that has been advanced into phase III trials for the treatment of a variety of cancers [<ce:cross-refs id="crosrefs0030" refid="bib29a bib29b bib29">29</ce:cross-refs>]. OPB-111077, a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation, is investigated in phase I trial in unselected advanced cancers (NCT01711034) [<ce:cross-ref id="crosref0155" refid="bib30">30</ce:cross-ref>]. C188-9, an oral STAT3 inhibitor targeting SH2 domain, is evaluated in phase I trial in the patients with advanced cancers (NCT03195699), which is also under development for the treatment of fibrosis and inflammation [<ce:cross-refs id="crosrefs0035" refid="bib31 bib31a bib31ab">31</ce:cross-refs>]. Overall, the discovery of novel potent STAT3 inhibitors remains to be further explored and developed.</ce:para>
                  <ce:para id="p0040" view="all">In our previous study, molecular docking-based virtual screening was applied to discover a STAT3 inhibitor with a benzothiazole scaffold targeting the Leu706-Phe 710 binding site of the STAT3 SH2 domain. Further investigation showed that compound <ce:bold>16w</ce:bold> exhibited potent inhibition of IL-6/STAT3 signaling with an IC<ce:inf loc="post">50</ce:inf> value of 1.6 μM as determined by a luciferase reporter assay [<ce:cross-ref id="crosref0160" refid="bib32">32</ce:cross-ref>]. With the aim of obtaining more potent STAT3 signaling inhibitors, rational drug design based on <ce:bold>16w</ce:bold> was carried out in this study. Among those designed compounds, <ce:bold>B19</ce:bold> exhibited the most potent inhibitory activity towards IL-6/STAT3 signaling pathway, which was 24-fold more potent than hit compound <ce:bold>16w</ce:bold> according to the IC<ce:inf loc="post">50</ce:inf> values (0.067 μM vs 1.6 μM). Moreover, it displayed potent <ce:italic>in vitro</ce:italic> antiproliferative activities against MDA-MB-468 cells and HEL (<ce:italic>JAK2</ce:italic> V617F) cells, through inhibiting STAT3 signaling pathway.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Design</ce:section-title>
                     <ce:para id="p0045" view="all">Firstly, molecular docking of <ce:bold>16w</ce:bold> with STAT3 SH2 domain was conducted using the X-ray crystal structure of STAT3/DNA complex (PDB code: <ce:inter-ref id="intref0010" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>), and the proposed binding mode was depicted in <ce:cross-ref id="crosref0165" refid="fig2">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>A and B. For <ce:cross-ref id="crosref0170" refid="fig2">Fig. 2</ce:cross-ref>A, three hydrogen bonds were formed between compound <ce:bold>16w</ce:bold> and the amino acid residues Gln644, Glu638 and Gln635 of STAT3 protein (<ce:cross-ref id="crosref0175" refid="fig2">Fig. 2</ce:cross-ref>A). As shown in <ce:cross-ref id="crosref0180" refid="fig2">Fig. 2</ce:cross-ref>B and C, a hydrophobic cleft (S1) enclosed by the Phe716, Trp623, Ile659 residues was located near the ring A and various substituents with different sizes or electrical properties could be introduced to explore the inhibitory activities (compounds <ce:bold>B1</ce:bold>–<ce:bold>B14</ce:bold>, <ce:bold>B17</ce:bold>, <ce:bold>B18</ce:bold>). The aromatic ring B inserted into a hydrophobic pocket (S2) surrounded by Met648, Tyr640, Ile653, Ile711 residues and hydroxy or methoxyl was incorporated to form hydrogen-bond or hydrophobic interaction to improve the activities (compounds <ce:bold>B19</ce:bold>–<ce:bold>B23</ce:bold>). We also investigated the effect of chiral methyl group or the long alkyl chain (compounds <ce:bold>B15</ce:bold>, <ce:bold>B16, B24</ce:bold>–<ce:bold>B30</ce:bold>) or thioether bond (<ce:bold>B31</ce:bold>, <ce:bold>B32</ce:bold>) on the activity of STAT3 signaling pathway (<ce:cross-ref id="crosref0185" refid="fig2">Fig. 2</ce:cross-ref>C).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Chemistry</ce:section-title>
                     <ce:para id="p0050" view="all">To obtain benzothiazole-based derivatives <ce:bold>B1–B17</ce:bold>, a modified literature method was used (<ce:cross-refs id="crosrefs0040" refid="sch1 sch2">Schemes 1 and 2</ce:cross-refs>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>) [<ce:cross-ref id="crosref0190" refid="bib32">32</ce:cross-ref>]. Intermediate <ce:bold>2</ce:bold> was prepared from commercially available (S)-1 phenylethan-1-amine and 2-chloroacetyl chloride using triethylamine in 90% yield. Then it was condensed with 6-aminobenzothiazole-2-thiol in refluxing acetone to afford the key intermediate <ce:bold>3</ce:bold> in almost quantitative yield without affording N-nucleophilic addition byproduct. Treatment of the substituted 4-hydroxybenzoic acids (<ce:bold>4a</ce:bold>-<ce:bold>4n</ce:bold>) or <ce:bold>7b</ce:bold> with 2-bromopentane and potassium hydroxide in ethanol at 78 °C resulted in the formation of <ce:bold>5a</ce:bold>-<ce:bold>5n</ce:bold> or <ce:bold>8c</ce:bold> in about 50–80% yield. The intermediates <ce:bold>8a</ce:bold> and <ce:bold>8b</ce:bold> were prepared by Mitsunobu reaction among the appropriate substituted alcohols with <ce:bold>7a</ce:bold> in 38.9% and 64.0% yields respectively [<ce:cross-ref id="crosref0195" refid="bib33">33</ce:cross-ref>]. Then, compounds <ce:bold>8a</ce:bold>-<ce:bold>8c</ce:bold> were conveniently hydrolyzed to provide the corresponding acid <ce:bold>9a</ce:bold>-<ce:bold>9c</ce:bold> quantitatively. The benzoyl chloride derivatives (<ce:bold>6a</ce:bold>-<ce:bold>6n</ce:bold>, <ce:bold>10a</ce:bold>-<ce:bold>10c</ce:bold>) were prepared from corresponding benzoic acids (<ce:bold>5a-5n</ce:bold>, <ce:bold>9a-9c</ce:bold>) reacted with SOCl<ce:inf loc="post">2</ce:inf>. Subsequently, target compounds <ce:bold>B1–B17</ce:bold> were obtained, respectively, by the reaction between <ce:bold>3</ce:bold> and the corresponding acyl chloride (<ce:bold>6a</ce:bold>-<ce:bold>6n, 10a</ce:bold>-<ce:bold>10c</ce:bold>) in the presence of potassium carbonate at room temperature in dichloromethane (36.7–82.7% yields).</ce:para>
                     <ce:para id="p0055" view="all">The synthetic route for compounds <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold> was shown in <ce:cross-ref id="crosref0200" refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>. Formylation of 2-methylbenzene-1, 3-diol (<ce:bold>15</ce:bold>) with POCl<ce:inf loc="post">3</ce:inf>–DMF regio-selectively afforded the benzaldehyde derivative <ce:bold>16</ce:bold> in an excellent yield. Sequential O-alkylations were performed in the DMF to afford <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold> in 60.0–75.0% yields [<ce:cross-ref id="crosref0205" refid="bib34">34</ce:cross-ref>,<ce:cross-ref id="crosref0210" refid="bib35">35</ce:cross-ref>]. After O-methylation of compounds <ce:bold>16</ce:bold> and <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold>, oxidation was carried out under NaClO<ce:inf loc="post">2</ce:inf>/NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>·2H<ce:inf loc="post">2</ce:inf>O buffer solution (pH = 4.5) to provide <ce:bold>19a</ce:bold>-<ce:bold>19d</ce:bold> in 63.1–83.0% yields. The intermediates <ce:bold>13b</ce:bold>-<ce:bold>13d</ce:bold> were obtained after demethylation by BBr<ce:inf loc="post">3</ce:inf> (17% in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>). Condensation of the amines (<ce:bold>14a</ce:bold>-<ce:bold>14e</ce:bold>) with benzoyl chloride derivatives (<ce:bold>20a</ce:bold>-<ce:bold>20d</ce:bold>), which were prepared from the corresponding carboxylic acid (<ce:bold>19a</ce:bold>-<ce:bold>19e</ce:bold>) and SOCl<ce:inf loc="post">2</ce:inf>, provided the desired compounds <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold> in 18.0–70.4% yields (<ce:cross-ref id="crosref0215" refid="sch3">Scheme 3</ce:cross-ref>).</ce:para>
                     <ce:para id="p0060" view="all">Synthesis of compounds <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold> was depicted in <ce:cross-ref id="crosref0220" refid="sch4">Scheme 4</ce:cross-ref>
                        <ce:float-anchor refid="sch4"/></ce:float-anchor>. After selectively protecting one hydroxyl of the starting material <ce:bold>21</ce:bold> with benzyl (<ce:bold>22</ce:bold>), the remaining hydroxyl group was methylated with iodomethane to get compound <ce:bold>23</ce:bold> in almost quantitative yield. Then compound <ce:bold>26</ce:bold> was obtained by oxidation of the aldehyde group, removal of the benzyl group, and methylation of carboxyl group sequentially in a good yield. Subsequent alkylation of <ce:bold>26</ce:bold> under several conditions afforded compounds <ce:bold>27a</ce:bold>-<ce:bold>27d</ce:bold> in 41.9–93.5% yields [<ce:cross-refs id="crosrefs0045" refid="bib36 bib37 bib38 bib39 bib40">36–40</ce:cross-refs>], which were hydrolyzed under 1 M NaOH and CH<ce:inf loc="post">3</ce:inf>OH solution to afford <ce:bold>28a</ce:bold>-<ce:bold>28d</ce:bold> quantitatively. Finally, the carboxyl was converted to acyl chloride group (<ce:bold>29a</ce:bold>-<ce:bold>29d</ce:bold>) and condensed with the amino group of <ce:bold>14a</ce:bold> to obtain compounds <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold> in 30.0–35.0% yields.</ce:para>
                     <ce:para id="p0065" view="all">The synthetic route of compound <ce:bold>B31</ce:bold> was shown in <ce:cross-ref id="crosref0225" refid="sch5">Scheme 5</ce:cross-ref>
                        <ce:float-anchor refid="sch5"/></ce:float-anchor>. Intermediate <ce:bold>31</ce:bold> was prepared by coupling commercially available compound <ce:bold>30</ce:bold> with N-Boc-glycine using HATU and DIPEA in 92.8% yield. Then, removing the Boc group and coupling with 2-chloro-6-nitrobenzo<ce:italic>[d]</ce:italic>thiazole to get compound <ce:bold>33</ce:bold>, which was converted to <ce:bold>B31</ce:bold> by reduction of the nitro group and condensation with <ce:bold>20d</ce:bold> sequentially.</ce:para>
                     <ce:para id="p0070" view="all">Compound <ce:bold>B32</ce:bold> was synthesized as depicted in <ce:cross-ref id="crosref0230" refid="sch6">Scheme 6</ce:cross-ref>
                        <ce:float-anchor refid="sch6"/></ce:float-anchor>. Commercially available 2-chloro-6-aminobenzothiazole was converted to intermediate <ce:bold>36</ce:bold> followed by nucleophilic substitution reaction with ethyl glycolate to obtain <ce:bold>37</ce:bold> in 64.6% yield. After hydrolysis of the ethyl ester group of <ce:bold>37</ce:bold> and then condensation with intermediate <ce:bold>30,</ce:bold> the target compound <ce:bold>B32</ce:bold> was afforded.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Biological assays</ce:section-title>
                     <ce:section id="sec2.3.1" view="all">
                        <ce:label>2.3.1</ce:label>
                        <ce:section-title id="sectitle0055">Inhibitory activity on STAT3 transcription</ce:section-title>
                        <ce:para id="p0075" view="all">Compounds <ce:bold>B1–B18</ce:bold> were firstly subjected to test the IL6/STAT3 signaling pathway activities using a STAT3 luciferase reporter system and their IC<ce:inf loc="post">50</ce:inf> values were summarized in <ce:cross-ref id="crosref0235" refid="tbl1">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor> (compounds <ce:bold>LLL12</ce:bold> [<ce:cross-ref id="crosref0240" refid="bib26">26</ce:cross-ref>] and <ce:bold>16w</ce:bold> were used as positive controls). For the substituent groups at R<ce:sup loc="post">1</ce:sup> position, compound <ce:bold>B1</ce:bold> with a methyl group showed better inhibitory activity (IC<ce:inf loc="post">50</ce:inf> = 0.95 μM) than hit compound <ce:bold>16w</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 1.60 μM). Incorporation of big steric substituents, such as ethyl (<ce:bold>B7</ce:bold>) and n-propyl (<ce:bold>B8</ce:bold>), in this position was detrimental to the activity (IC<ce:inf loc="post">50</ce:inf> > 10 μM). Also, the presence of electron-withdrawing groups such as fluorine (<ce:bold>B3</ce:bold>), cyano (<ce:bold>B6</ce:bold>) and trifluoromethyl (<ce:bold>B9</ce:bold>) decreased the activity (IC<ce:inf loc="post">50</ce:inf> > 10 μM). Compounds <ce:bold>B2</ce:bold> and <ce:bold>B5</ce:bold> with methoxyl and bromine at this position displayed similar activities to <ce:bold>16w</ce:bold> with IC<ce:inf loc="post">50</ce:inf> values of 1.42 μM and 2.15 μM, respectively. For the substituent groups at R<ce:sup loc="post">2</ce:sup> position, there exists a similar trend as R<ce:sup loc="post">1</ce:sup> group. Substituent groups methyl (<ce:bold>B10</ce:bold>), methoxy (<ce:bold>B11</ce:bold>) and chlorine (<ce:bold>B13</ce:bold>) maintained the activities, while electron withdrawing group fluorine (<ce:bold>B12</ce:bold>) led to a significant loss of potency. Since there was a chiral methyl group at the long alkyl chain, we then investigated its effect on the activity. As shown in <ce:cross-ref id="crosref0245" refid="tbl2">Table 2</ce:cross-ref>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor>, the <ce:italic>R</ce:italic> configuration showed a better luciferase activity than <ce:italic>S</ce:italic> configuration (<ce:bold>B15</ce:bold> vs <ce:bold>B16</ce:bold>). Furthermore, the introduction of a methyl (<ce:bold>B17</ce:bold>) or a methoxyl group (<ce:bold>B18</ce:bold>) at R<ce:sup loc="post">2</ce:sup> position resulted in a 2-fold or 6-fold increased activity respectively (<ce:bold>B17</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 0.46 μM; <ce:bold>B18</ce:bold> IC<ce:inf loc="post">50</ce:inf> = 0.16 μM). Presumably the formation of an intramolecular hydrogen bond between OCH<ce:inf loc="post">3</ce:inf> and the adjacent NH of amide in compound <ce:bold>B18</ce:bold> made the amide and the benzene ring in the same plane，and thus restricted the degrees of freedom. For this reason, <ce:bold>B18</ce:bold> was probably maintained in a preferred conformation. Therefore, the methyl at R<ce:sup loc="post">1</ce:sup> position could fit into the desired pocket more appropriately and increased the binding affinity with the target [<ce:cross-ref id="crosref0250" refid="bib41">41</ce:cross-ref>].</ce:para>
                        <ce:para id="p0080" view="all">To further improve the potency of <ce:bold>B18</ce:bold>, it was envisioned that an additional hydrogen-bond or some hydrophobic interaction could be formed after introducing a hydroxy or methoxy at some positions of aromatic ring B. As shown in <ce:cross-ref id="crosref0255" refid="tbl3">Table 3</ce:cross-ref>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>, compound <ce:bold>B19</ce:bold> with a methoxyl group at the para position exhibited the most potent activity with an IC<ce:inf loc="post">50</ce:inf> value of 0.067 μM, which was better than a hydroxy substituted at the same position (<ce:bold>B21</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 0.20 μM<ce:bold>)</ce:bold> and a methoxyl group at the meta position (<ce:bold>B20,</ce:bold> IC<ce:inf loc="post">50</ce:inf> = 0.27 μM). However, activities of compounds with a hydroxy substituent at the ortho (<ce:bold>B23</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 0.17 μM) or meta (<ce:bold>B22</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 0.15 μM) position were comparable to that of compound <ce:bold>B18</ce:bold>. With the goals of improving solubility or simplify the molecule, we sought to shorten the long alkyl chain or replaced it with hydrophilic functional groups (<ce:bold>B24</ce:bold>–<ce:bold>B30</ce:bold>). As shown in <ce:cross-ref id="crosref0260" refid="tbl3">Table 3</ce:cross-ref>, compared with <ce:bold>B18</ce:bold>, all resulting compounds showed reduced activities with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.20 μM to 1.03 μM, which might be due to the hydrophobic interactions between the alkyl chain and the target. Unfortunately, replacing the S atom of thioether with NH (<ce:bold>B31</ce:bold>) or O (<ce:bold>B32</ce:bold>) brought a significant drop of activities.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.2" view="all">
                        <ce:label>2.3.2</ce:label>
                        <ce:section-title id="sectitle0060">In vitro cell growth inhibitory activity</ce:section-title>
                        <ce:para id="p0085" view="all">Compounds that displayed better inhibitory activity on STAT3 transcription were firstly evaluated for their antiproliferative activities against human erythroleukemia (HEL) cells bearing <ce:italic>JAK2</ce:italic> V617F mutation that results in constitutive activation of STAT3. JAK1/2 inhibitors <ce:bold>INC18424</ce:bold> and <ce:bold>AZD1480</ce:bold> were used as positive controls. As shown in <ce:cross-ref id="crosref0265" refid="tbl4">Table 4</ce:cross-ref>
                           <ce:float-anchor refid="tbl4"/></ce:float-anchor>, compared to the hit compound <ce:bold>16w</ce:bold>, all of these selected compounds exhibited potent activities toward HEL (<ce:italic>JAK2</ce:italic> V617F) cells except for <ce:bold>B1</ce:bold> and <ce:bold>B28</ce:bold>. Additionally, those compounds were tested their antiproliferative activities against STAT3 over-expressed human breast cancer cell line MDA-MB-468 using MTT assay. The IC<ce:inf loc="post">50</ce:inf> values were listed in <ce:cross-ref id="crosref0270" refid="tbl4">Table 4</ce:cross-ref> and all the compounds showed growth inhibitory effect on the MDA-MB-468 cells with IC<ce:inf loc="post">50</ce:inf> values ranging from sub-micromole to micromole (0.25 μM–6.57 μM). In particular, compound <ce:bold>B19</ce:bold> exhibiting the best STAT3-induced luciferase activity (IC<ce:inf loc="post">50</ce:inf> = 0.067 μM) also displayed the most potent activity against MDA-MB-468 cells (IC<ce:inf loc="post">50</ce:inf> = 0.25 μM). In contrast, <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> showed no antiproliferative activities against MDA-MB-453 and MCF-7 cell lines, which were generally reported with low expression levels of STAT3 [<ce:cross-ref id="crosref0275" refid="bib42">42</ce:cross-ref>], with IC<ce:inf loc="post">50</ce:inf> values greater than 20 μM (<ce:cross-ref id="crosref0280" refid="tbl5">Table 5</ce:cross-ref>
                           <ce:float-anchor refid="tbl5"/></ce:float-anchor>). These data together suggested that a subset of compounds with potent antiproliferative activity were worth further evaluation.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.3" view="all">
                        <ce:label>2.3.3</ce:label>
                        <ce:section-title id="sectitle0065">Western blot analysis</ce:section-title>
                        <ce:para id="p0090" view="all">Based on the results of inhibitory activities on STAT3 transcription and cell proliferation, we next proceeded to evaluate the inhibitory effect of compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> on STAT3 signaling pathway in HEL (<ce:italic>JAK2</ce:italic> V617F) and MDA-MB-468 cells by Western blot analysis. STAT3 phosphorylation at Tyr705 residue can lead to its homodimerization, translocation into nucleus, DNA-binding and downstream transcriptional activities. There is an increasing understanding about phosphorylation at Ser727 residue, which is associated with the transcription, mitochondrial import and other biological functions of STAT3 [<ce:cross-ref id="crosref0285" refid="bib43">43</ce:cross-ref>]. Therefore, the STAT3 phosphorylation level at Tyr705 and Ser727 was evaluated. As shown in <ce:cross-ref id="crosref0290" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>, these two compounds could inhibit STAT3 phosphorylation at Tyr705 and Ser727 in both cell lines without influence on the total expression of STAT3 protein after 24 h incubation. Aberrant STAT3 signaling has been shown to promote tumor progression through directly or indirectly upregulating the expression of downstream target genes, such as cell-cycle regulator <ce:italic>c-MYC</ce:italic> and an anti-apoptotic gene <ce:italic>MCL-1</ce:italic> [<ce:cross-ref id="crosref0295" refid="bib44">44</ce:cross-ref>,<ce:cross-ref id="crosref0300" refid="bib45">45</ce:cross-ref>]. Compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> significantly reduced the protein level of c-Myc and MCL-1. Overall, the results indicated these compounds efficiently inhibited STAT3 signaling pathway.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.4" view="all">
                        <ce:label>2.3.4</ce:label>
                        <ce:section-title id="sectitle0070">In vitro kinases activity test</ce:section-title>
                        <ce:para id="p0095" view="all">To further evaluate the selectivity of compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> against the upstream kinases which could activate STAT3 signaling pathway, enzyme-linked immunosorbent assay (ELISA) was employed to test a panel of kinases. As shown in <ce:cross-ref id="crosref0305" refid="tbl6">Table 6</ce:cross-ref>
                           <ce:float-anchor refid="tbl6"/></ce:float-anchor>, we investigated the inhibitory effects of compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> on eleven receptor tyrosine kinases. Encouragingly, all of our compounds had no effect against these kinases, which clearly manifested that the inhibition of p-STAT3 was not owing to the inhibition of upstream kinases.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.5" view="all">
                        <ce:label>2.3.5</ce:label>
                        <ce:section-title id="sectitle0075">The selectivity against related IFN-γ/STAT1 and TNF-α/NF-κB signaling pathways</ce:section-title>
                        <ce:para id="p0100" view="all">To our knowledge, IFN-γ/STAT1 and TNF-α/NF-κB signaling pathways are two closely related intracellular signaling pathways with IL-6/STAT3 signaling pathway. The former is the structural homologous signaling pathway, and the latter is the functional homologous signaling pathway. Therefore, the selectivity of compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> against these two signaling pathway was investigated using a STAT1 luciferase reporter gene assay in HepG2 cells and a NF-κB luciferase reporter gene assay in HEK-293 cells. As shown in <ce:cross-ref id="crosref0310" refid="tbl7">Table 7</ce:cross-ref>
                           <ce:float-anchor refid="tbl7"/></ce:float-anchor>, compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> did not display any of TNF-α-induced NF-κB activations with a concentration as high as 100 μM. However, both compounds showed little selectivity for STAT3 signaling over IFN-γ/STAT1 signaling pathway, probably owing to the high structural homology of the SH2 domain among the STAT proteins. Thus, improving STAT isoform selectivity remains a goal for future compound optimization.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.6" view="all">
                        <ce:label>2.3.6</ce:label>
                        <ce:section-title id="sectitle0080">Apoptosis induction and G2/M cell-cycle arrest in MDA-MB-468 and HEL cells</ce:section-title>
                        <ce:para id="p0105" view="all">As compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> displayed potent antiproliferative potency toward both MDA-MB-468 and HEL (<ce:italic>JAK2</ce:italic> V617F) cell lines, we then investigated the effect of them on the induction of cells apoptosis by flow cytometry. As shown in <ce:cross-ref id="crosref0315" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>A, compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> induced apoptosis of the test cells at the concentrations of 1.25 μM, 2.5 μM and 5.0 μM, which demonstrated that <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> could effectively inhibit cancer cell growth through apoptosis induction. Also, the effect of <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> on cell cycle progression of MDA-MB-468 and HEL (<ce:italic>JAK2</ce:italic> V617F) cells was determined using flow cytometry and the results were shown in <ce:cross-ref id="crosref0320" refid="fig4">Fig. 4</ce:cross-ref>B. After treatment with compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> for 48 h, the proportion of cells in G2/M phase was increased accompanying with a decrease of cells in G1 phase in a dose-dependent behavior.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.7" view="all">
                        <ce:label>2.3.7</ce:label>
                        <ce:section-title id="sectitle0085">SPR assay</ce:section-title>
                        <ce:para id="p0110" view="all">To determine the binding affinity and kinetic parameters of our representative compounds toward STAT3 SH2 domain, surface plasmon resonance (SPR) assay was employed using a Biacore T200 optical biosensor. Firstly, the reported STAT3 SH2 domain binders 5-FAM-GpYLPQTV-NH2 derived peptide (<ce:bold>Sub</ce:bold>) [<ce:cross-ref id="crosref0325" refid="bib46">46</ce:cross-ref>] and <ce:bold>Stattic</ce:bold> [<ce:cross-ref id="crosref0330" refid="bib47">47</ce:cross-ref>] were used as positive controls. As shown in <ce:cross-ref id="crosref0335" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>, the equilibrium constant <ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf> values of compounds <ce:bold>Sub</ce:bold> and <ce:bold>Stattic</ce:bold> were 28.81 nM and 1528 nM respectively. For our representative compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold>, the response unit (RU) values were proportional to compound concentrations within the selected ranges and the <ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf> values were 62.61 nM (<ce:bold>B18</ce:bold>) and 53.04 nM (<ce:bold>B19</ce:bold>) respectively, which indicated a strong binding affinity to STAT3 SH2 domain.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.8" view="all">
                        <ce:label>2.3.8</ce:label>
                        <ce:section-title id="sectitle0090">Fluorescence polarization (FP) assay</ce:section-title>
                        <ce:para id="p0115" view="all">It has been reported that the binding site of 5-FAM-GpYLPQTV-NH<ce:inf loc="post">2</ce:inf> derived peptide (<ce:bold>Sub</ce:bold>) and <ce:bold>Sttatic</ce:bold> was pTyr705 site in SH2 domain of STAT3 [<ce:cross-ref id="crosref0340" refid="bib46">46</ce:cross-ref>,<ce:cross-ref id="crosref0345" refid="bib47">47</ce:cross-ref>]. To exclude the directly binding at pTyr705 site of our compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold>, FP-based competition binding assay was conducted according to previously reported method [<ce:cross-ref id="crosref0350" refid="bib47">47</ce:cross-ref>,<ce:cross-ref id="crosref0355" refid="bib48">48</ce:cross-ref>]. Firstly, this derived peptide was applied as the fluorescent probe with the <ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf> value of 186.4 nM in our experiment, which was almost equivalent to the reported value (<ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf> = 150 nM) by Berg and coworker [<ce:cross-ref id="crosref0360" refid="bib46">46</ce:cross-ref>]. As shown in <ce:cross-ref id="crosref0365" refid="tbl8">Table 8</ce:cross-ref>
                           <ce:float-anchor refid="tbl8"/></ce:float-anchor>, <ce:bold>Stattic</ce:bold> could bind to STAT3 protein in a concentration-dependent manner, indicating its binding position at pTyr705 site in SH2 domain. However, compounds <ce:bold>B18</ce:bold> and <ce:bold>B19</ce:bold> did not show any competition with the probe even at a concentration of 100 μM, which indicates their binding site was different from <ce:bold>Stattic</ce:bold> and the probe (<ce:bold>Sub</ce:bold>).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.9" view="all">
                        <ce:label>2.3.9</ce:label>
                        <ce:section-title id="sectitle0095">Molecular docking study</ce:section-title>
                        <ce:para id="p0120" view="all">As <ce:bold>B19</ce:bold> exhibited the most potent inhibitory activity in luciferase reporter assay among all designed compounds, a docking model of <ce:bold>B19</ce:bold> bound to SH2 domain was generated on the basis of the crystal structure of the STAT3β homodimer (PDB code <ce:inter-ref id="intref0015" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) by Schrodinger, Maestro suite. As illustrated in <ce:cross-ref id="crosref0370" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>B, <ce:bold>B19</ce:bold> located at the Leu706-Phe 710 (Phe710-lys709-thr708-lys707-leu706) binding site in STAT3 SH2 domain rather than the pY705 site and acted as a partial peptidomimetic of phosphotyrosine peptide (pYLKTKF). The left amide NH and the right amide C<ce:glyph name="dbnd"/></ce:glyph>O formed two hydrogen bonds with Gln644 and Glu638 respectively. In addition, the oxygen atom close to the long alkyl chain formed one hydrogen bond with the amide group of Gln635 (<ce:cross-ref id="crosref0375" refid="fig6">Fig. 6</ce:cross-ref>C). The 4-methoxy-<ce:italic>S</ce:italic>-methyl benzylamine group occupied the hydrophobic pocket surrounded by Met648、Tyr640、Ile653、Ile711 residues (S2) in a manner similar to Phe710 of the phosphotyrosine peptide. The methyl on the right benzene ring fitted perfectly the expectant hydrophobic cleft described before and enhanced the binding affinity via hydrophobic interactions with Phe716, Ile659 and Trp623. Intriguingly, the O atom of the methoxyl adjacent to this methyl group could form an intramolecular hydrogen bond with the NH of amide, which was conductive to the insertion of methyl into the described hydrophobic cleft and made a great improvement on activity (<ce:cross-ref id="crosref0380" refid="fig6">Fig. 6</ce:cross-ref>D).</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0100">Conclusions</ce:section-title>
                  <ce:para id="p0125" view="all">In this work, we reported a series of potent STAT3 inhibitors by optimizing the previously identified benzothiazole derivatives. Among the tested compounds, we found that compound <ce:bold>B19</ce:bold> exhibited the most potent activities against STAT3 transcription and inhibited cancer cell growth, such as MDA-MB-468 and HEL (<ce:italic>JAK2</ce:italic> V617F) cells, at low micromole concentration. Further biochemical study demonstrated that <ce:bold>B19</ce:bold> could dose-dependently inhibited STAT3 phosphorylation at Tyr705 and Ser727, as well as the downstream gene expression (<ce:italic>c-MYC</ce:italic> and <ce:italic>MCL-1</ce:italic>). In addition, compound <ce:bold>B19</ce:bold> was highly selective for the IL-6/STAT3 signaling pathway over TNF-α/NF-κB signaling pathway and some upstream kinases. Mechanistically, we elucidated the predicted binding mode of <ce:bold>B19</ce:bold> at the Leu706-Phe 710 binding site of STAT3 SH2 domain using SPR, FP and molecular docking studies. All of those results indicated that targeting the Leu706-Phe710 binding site in STAT3 SH2 could prevent either STAT3 recruitment to the receptor and phosphorylation at Tyr705 by JAKs, or the formation of STAT3 dimerization, subsequently inhibiting the translocation of STAT3 dimers to nucleus to induce transcription of downstream genes. However, <ce:bold>B19</ce:bold> exhibited poor oral exposures with low area under the concentration time curve (AUC<ce:inf loc="post">last</ce:inf>) values (3 mg/kg, 2.50 h ng/mL) which may be caused by the poor solubility, the oxidative metabolism of S atom, the hydrolysis of two amide bond or the cleavage of carbon-sulfur bond. Accordingly, several structural optimizations to improve metabolism stability should be conducted in the future work, including bioisosteric replacement of the amide bond, incorporation of methyl, fluoro, <ce:italic>gem</ce:italic>-dimethyl or <ce:italic>gem</ce:italic>-difluoro at the methylene position to improve the oxidative metabolism, and introduction of heteroatoms to reduce the lipophilicity.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0105">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0110">Chemistry</ce:section-title>
                     <ce:para id="p0130" view="all">All the reagents and solvents were purchased from Adamas-beta®, Energy Chemical or Bide pharmatech and were used without further purification unless otherwise noted. Anhydrous solvents were purchased from Adamas-beta®. <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra were recorded on a 400 MHz Varian spectrometer or a 600 MHz Bruker spectrometer at 303 K and referenced to TMS. <ce:sup loc="post">19</ce:sup>F NMR spectrum was recorded on a 600 MHz Bruker spectrometer at 303 K. Chemical shifts are reported in parts per million (ppm, <ce:italic>δ</ce:italic>). Proton coupling patterns are described as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; brs, broad singlet. Mass spectra data were obtained on Agilent Technologies 1260 infinity LC/MS instrument (ESI-MS) and High-resolution mass spectra (HRMS) data were given by AB 5600 + Q TOF. Analytical and preparative TLCs were performed on silica gel HSGF/UV 254. The chromatograms were conducted on silica gel (200–300 mesh) and visualized under UV light at 254 and 365 nm.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0115">General procedures for the synthesis of <ce:bold>B1</ce:bold>–<ce:bold>B14</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0135" view="all">The synthesis of the products <ce:bold>B1</ce:bold>–<ce:bold>B14</ce:bold> from 4-hydrobenzoic acid derivatives and (<ce:italic>S</ce:italic>) methyl benzylamine was previously reported in ref. 32.</ce:para>
                        <ce:section id="sec4.1.1.1" view="all">
                           <ce:label>
                              <ce:italic>4.1.1.1</ce:italic>
                           </ce:label>
                           <ce:section-title id="sectitle0120">
                              <ce:italic>3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)Benzo[d]thiazol-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide</ce:italic> (<ce:bold>B1</ce:bold>)</ce:section-title>
                           <ce:para id="p0140" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-methyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6a</ce:bold>, 0.24 mmol, 57.8 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (90.2 mg, 82.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.24 (s, 1H), 8.78 (d, <ce:italic>J</ce:italic> = 7.82 Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 1.57 Hz, 1H), 7.80–7.70 (m, 4H), 7.31–7.24 (m, 4H), 7.19 (t, <ce:italic>J</ce:italic> = 7.04 Hz, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 8.22 Hz, 1H), 4.95–4.85 (m, 1H), 4.60–4.52 (m, 1H), 4.17 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 2.18 (s, 3H), 1.70–1.62 (m, 1H), 1.60–1.52 (m, 1H), 1.48–1.33 (m, 5H), 1.25 (d, <ce:italic>J</ce:italic> = 5.87 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.43 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.13, 164.92, 164.02, 158.32, 148.32, 143.77, 135.86, 134.81, 129.78, 127.84, 126.88, 126.31, 125.88, 125.52, 125.43, 120.40, 119.36, 112.06, 111.28, 72.71, 48.11, 37.63, 36.27, 22.05, 19.18, 17.70, 15.86, 13.56. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 548.2036, found: 548.2039.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.2" view="all">
                           <ce:label>4.1.1.2</ce:label>
                           <ce:section-title id="sectitle0125">3-Methoxy-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] <ce:italic>thiazol-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide (</ce:italic>
                              <ce:bold>B2</ce:bold>
                              <ce:italic>)</ce:italic>
                           </ce:section-title>
                           <ce:para id="p0145" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-methoxy-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6b</ce:bold>, 0.24 mmol, 61.6 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (73.1 mg, 64.9% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.25 (s, 1H), 8.76 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.44 (d, <ce:italic>J</ce:italic> = 1.5 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.71 (dd, <ce:italic>J</ce:italic> = 8.9, 1.7 Hz, 1H), 7.56 (dd, <ce:italic>J</ce:italic> = 8.4, 1.6 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 7.33–7.22 (m, 4H), 7.17 (t, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 7.07 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 4.94–4.84 (m, 1H), 4.56–4.46 (m, 1H), 4.16 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 3.81 (s, 3H), 1.69–1.59 (m, 1H), 1.56–1.46 (m, 1H), 1.43–1.29 (m, 5H), 1.21 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.87 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.60, 165.20, 164.62, 150.22, 149.24, 148.91, 144.26, 136.20, 135.29, 128.33, 126.79, 126.70, 126.02, 121.16, 120.89, 120.04, 113.57, 112.82, 111.61, 73.76, 55.74, 48.58, 38.04, 36.77, 22.54, 19.59, 18.22, 14.00. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S<ce:inf loc="post">2</ce:inf>: 564.1985, found: 564.1983.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.3" view="all">
                           <ce:label>4.1.1.3</ce:label>
                           <ce:section-title id="sectitle0130">3-Fluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B3</ce:bold>)</ce:section-title>
                           <ce:para id="p0150" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-fluoro-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6c</ce:bold>, 0.24 mmol, 58.7 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (91.2 mg, 82.7% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.34 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 8.48 (s, 1H), 7.87–7.69 (m, 4H), 7.36–7.15 (m, 6H), 4.95–4.85 (m, 1H), 4.68–4.58 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 1.72–1.61 (m, 1H), 1.59–1.50 (m, 1H), 1.47–1.34 (m, 5H), 1.27 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.93, 165.14, 164.39, 153.31, 150.89, 149.41, 149.01, 144.64, 136.40, 135.71, 128.69, 127.16, 126.41, 125.37, 121.31, 120.31, 116.17, 116.01, 113.14, 75.28, 48.95, 38.27, 37.20, 22.88, 19.89, 18.49, 14.32.<ce:sup loc="post">19</ce:sup>F NMR (565 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> −131.83. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">31</ce:inf>FN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 552.1785, found: 552.1781.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.4" view="all">
                           <ce:label>4.1.1.4</ce:label>
                           <ce:section-title id="sectitle0135">3-Chloro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol<ce:italic>-</ce:italic>6-yl<ce:italic>)-4-(pentan-2-yloxy)benzamide (</ce:italic>
                              <ce:bold>B4</ce:bold>
                              <ce:italic>)</ce:italic>
                           </ce:section-title>
                           <ce:para id="p0155" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-chloro-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6d</ce:bold>, 0.24 mmol, 62.7 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (68.8 mg, 60.7% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.38 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 8.47 (s, 1H), 8.06 (s, 1H), 7.92 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.81–7.68 (m, 2H), 7.36–7.16 (m, 5H), 4.95–4.85 (m, 1H), 4.71–4.61 (m, 1H), 4.23–4.09 (m, 2H), 1.74–1.63 (m, 1H), 1.63–1.54 (m, 1H), 1.51–1.39 (m, 2H), 1.36 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H), 1.28 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.45, 164.68, 163.81, 155.84, 148.89, 144.15, 135.87, 135.19, 129.44, 128.37, 128.20, 127.13, 126.66, 125.90, 121.85, 120.80, 119.80, 114.22, 112.66, 74.74, 48.45, 37.75, 36.65, 22.41, 19.36, 17.94, 13.84. ESI-HRMS [M + H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">31</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 568.1490, found: 568.1487.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.5" view="all">
                           <ce:label>4.1.1.5</ce:label>
                           <ce:section-title id="sectitle0140">3-Bromo-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B5</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-bromo-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6e</ce:bold>, 0.24 mmol, 73.3 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (74.3 mg, 60.6% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.38 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.46 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 8.21 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.96 (dd, <ce:italic>J</ce:italic> = 8.7, 2.0 Hz, 1H), 7.80–7.67 (m, 2H), 7.40–7.10 (m, 6H), 4.95–4.85 (m, 1H), 4.70–4.61 (m, 1H), 4.17 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.73–1.63 (m, 1H), 1.62–1.53 (m, 1H), 1.50–1.33 (m, 5H), 1.28 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.65, 164.84, 163.89, 156.89, 149.04, 144.29, 136.01, 135.34, 132.60, 129.20, 128.36, 127.69, 126.83, 126.04, 120.96, 119.98, 114.13, 112.84, 111.72, 74.97, 48.64, 37.94, 36.79, 22.56, 19.52, 18.10, 14.02. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">31</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 614.0967, found: 614.0963.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.6" view="all">
                           <ce:label>4.1.1.6</ce:label>
                           <ce:section-title id="sectitle0145">3-Cyano-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B6</ce:bold>)</ce:section-title>
                           <ce:para id="p0165" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-cyano-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6f</ce:bold>, 0.24 mmol, 60.4 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (96.2 mg, 86.2% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.46 (s, 1H), 8.80 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.51 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 8.39 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 8.24 (dd, <ce:italic>J</ce:italic> = 9.0, 2.3 Hz, 1H), 7.82 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.74 (dd, <ce:italic>J</ce:italic> = 8.9, 2.0 Hz, 1H), 7.46 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H), 7.36–7.27 (m, 4H), 7.25–7.19 (m, 1H), 4.98–4.88 (m, 1H), 4.84–4.74 (m, 1H), 4.21 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.17 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.78–1.68 (m, 1H), 1.67–1.58 (m, 1H), 1.51–1.36 (m, 5H), 1.34 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.93 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.31, 164.66, 163.14, 161.71, 148.87, 144.00, 135.61, 135.11, 134.67, 133.26, 128.06, 126.73, 126.53, 125.78, 120.73, 119.63, 115.79, 113.64, 112.52, 100.88, 75.29, 48.33, 37.45, 36.57, 22.23, 19.09, 17.72, 13.66. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">31</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 559.1832, found: 559.1833.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.7" view="all">
                           <ce:label>4.1.1.7</ce:label>
                           <ce:section-title id="sectitle0150">3-Ethyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B7</ce:bold>)</ce:section-title>
                           <ce:para id="p0170" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 3-ethyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6g</ce:bold>, 0.24 mmol, 61.2 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (56.7 mg, 50.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.24 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 7.83–7.70 (m, 4H), 7.33–7.23 (m, 4H), 7.19 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 7.07 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.95–4.85 (m, 1H), 4.64–4.54 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.8, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.8, 1H), 2.59 (q, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 1.72–1.62 (m, 1H), 1.61–1.51 (m, 1H), 1.50–1.34 (m, 5H), 1.24 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 1.15 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.46, 165.29, 164.38, 158.20, 148.71, 144.15, 136.23, 135.17, 132.11, 128.73, 128.20, 127.22, 126.66, 125.90, 120.75, 119.78, 112.51, 111.63, 72.66, 48.45, 38.00, 36.65, 23.09, 22.40, 19.39, 18.07, 14.11, 13.91. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 562.2193, found: 562.2193.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.8" view="all">
                           <ce:label>4.1.1.8</ce:label>
                           <ce:section-title id="sectitle0155">N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-<ce:italic>(pentan-2-yloxy)-3-propylbenzamide (</ce:italic>
                              <ce:bold>B8</ce:bold>
                              <ce:italic>)</ce:italic>
                           </ce:section-title>
                           <ce:para id="p0175" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 4-(pentan-2-yloxy)-3-propylbenzoyl chloride (<ce:bold>6h</ce:bold>, 0.24 mmol, 64.5 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (50.0 mg, 43.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.23 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.83–7.70 (m, 4H), 7.33–7.23 (m, 4H), 7.19 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 7.07 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 4.95–4.85 (m, 1H), 4.63–4.54 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 2.55 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.73–1.38 (m, 6H), 1.36 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H), 1.24 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.45, 165.25, 164.36, 158.32, 148.72, 144.14, 136.25, 135.17, 130.54, 129.53, 128.20, 127.26, 126.66, 125.91, 125.77, 120.75, 119.79, 112.52, 111.67, 72.62, 48.45, 38.00, 36.69, 31.88, 22.49, 22.39, 19.34, 18.02, 13.92, 13.88. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">38</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 576.2349, found: 576.2350.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.9" view="all">
                           <ce:label>4.1.1.9</ce:label>
                           <ce:section-title id="sectitle0160">N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4- <ce:italic>(pentan-2-yloxy)-3-(trifluoromethyl)benzamide (</ce:italic>
                              <ce:bold>B9</ce:bold>
                              <ce:italic>)</ce:italic>
                           </ce:section-title>
                           <ce:para id="p0180" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 4-(pentan-2-yloxy)-3-(trifluoromethyl) benzoyl chloride (<ce:bold>6i</ce:bold>, 0.24 mmol, 70.7 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (56.3 mg, 46.8% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.40 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 8.24 (s, 1H), 8.13–8.06 (m, 2H), 7.87 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.44 (dd, <ce:italic>J</ce:italic> = 8.7, 2.0 Hz, 1H), 7.24–7.17 (m, 4H), 7.07 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 5.11–5.01 (m, 1H), 4.64–4.54 (m, 1H), 3.96 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 3.91 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.86–1.76 (m, 1H), 1.70–1.60 (m, 2H), 1.56–1.47 (m, 1H), 1.44 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H), 1.37 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.93, 165.23, 164.36, 158.81, 149.48, 144.64, 136.33, 135.71, 134.40, 128.69, 127.16, 126.41, 126.35, 121.31, 120.41, 114.59, 113.32, 74.96, 48.95, 38.25, 37.20, 22.88, 19.61, 18.24, 14.28.<ce:sup loc="post">19</ce:sup>F NMR (565 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> −62.68. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">31</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 602.1753, found: 602.1751.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.10" view="all">
                           <ce:label>4.1.1.10</ce:label>
                           <ce:section-title id="sectitle0165">2-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B10</ce:bold>)</ce:section-title>
                           <ce:para id="p0185" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 2-methyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6j</ce:bold>, 0.24 mmol, 57.8 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (44.5 mg, 40.7% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.36 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.48 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.64 (dd, <ce:italic>J</ce:italic> = 8.9, 1.8 Hz, 1H), 7.42 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.35–7.15 (m, 5H), 6.81 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 4.94–4.84 (m, 1H), 4.54–4.46 (m, 1H), 4.16 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.11 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 2.36 (s, 3H), 1.67–1.58 (m, 1H), 1.56–1.48 (m, 1H), 1.46–1.32 (m, 5H), 1.21 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.87 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 167.93, 165.78, 164.42, 159.08, 148.88, 144.35, 138.34, 136.52, 135.51, 129.58, 128.96, 128.45, 126.93, 126.12, 121.11, 119.30, 117.83, 112.20, 111.93, 72.89, 48.72, 38.13, 36.81, 22.62, 20.00, 19.71, 18.34, 14.10. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 548.2036, found: 548.2034.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.11" view="all">
                           <ce:label>4.1.1.11</ce:label>
                           <ce:section-title id="sectitle0170">2-Methoxy-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B11</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 2-methoxy-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6k</ce:bold>, 0.24 mmol, 61.6 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (45.6 mg, 40.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.91 (s, 1H), 8.55 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 8.24 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.7, 2.1 Hz, 1H), 7.25–7.16 (m, 5H), 6.64 (dd, <ce:italic>J</ce:italic> = 8.9, 2.2 Hz, 1H), 6.53 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 5.11–5.02 (m, 1H), 4.54–4.44 (m, 1H), 4.05 (s, 3H), 3.96 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 3.89 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.79–1.75 (m, 1H), 1.63–1.57 (m, 1H), 1.54–1.41 (m, 5H), 1.34 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 167.39, 165.08, 163.32, 162.78, 158.66, 148.60, 142.88, 136.53, 135.86, 134.16, 128.57, 127.22, 125.92, 121.05, 119.37, 113.71, 112.43, 106.96, 100.21, 73.95, 56.23, 49.39, 38.45, 36.32, 22.00, 19.66, 18.71, 14.02. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S<ce:inf loc="post">2</ce:inf>: 564.1985, found: 564.1989.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.12" view="all">
                           <ce:label>4.1.1.12</ce:label>
                           <ce:section-title id="sectitle0175">2-Fluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol -6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B12</ce:bold>)</ce:section-title>
                           <ce:para id="p0195" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 2-fluoro-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6l</ce:bold>, 0.24 mmol, 58.7 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (52.7 mg, 47.8% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.39 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.46 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.66–7.58 (m, 2H), 7.34–7.23 (m, 4H),7.22–7.16 (m, 1H), 6.94 (dd, <ce:italic>J</ce:italic> = 12.7, 2.0 Hz, 1H), 6.87 (dd, <ce:italic>J</ce:italic> = 8.6, 2.1 Hz, 1H), 4.95–4.84 (m, 1H), 4.63–4.53 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.67–1.58 (m, 1H), 1.57–1.49 (m, 1H), 1.46–1.30 (m, 5H), 1.24 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.96, 165.15, 163.08, 162.12, 161.72, 159.64, 149.37, 144.63, 136.33, 135.82, 131.70, 128.70, 127.17, 126.40, 121.42, 119.71, 116.72, 112.34, 103.46, 74.17, 48.96, 38.22, 37.17, 22.87, 19.80, 18.52, 14.32.<ce:sup loc="post">19</ce:sup>F NMR (565 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> −110.46. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">31</ce:inf>FN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 552.1785, found: 552.1790.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.13" view="all">
                           <ce:label>4.1.1.13</ce:label>
                           <ce:section-title id="sectitle0180">2-Chloro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B13</ce:bold>)</ce:section-title>
                           <ce:para id="p0200" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 2-chloro-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6m</ce:bold>, 0.24 mmol, 62.7 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (59.5 mg, 52.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.59 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 1.5 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.62 (dd, <ce:italic>J</ce:italic> = 8.8, 1.7 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.32–7.22 (m, 4H), 7.19 (t, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 7.09 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.99 (dd, <ce:italic>J</ce:italic> = 8.6, 2.2 Hz, 1H), 4.95–4.84 (m, 1H), 4.61–4.52 (m, 1H), 4.17 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 1.67–1.59 (m, 1H), 1.56–1.48 (m, 1H), 1.45–1.29 (m, 5H), 1.23 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 170.70, 170.13, 169.91, 164.57, 154.05, 150.97, 149.32, 141.04, 140.56, 136.51, 135.57, 133.81, 133.41, 131.89, 131.09, 129.02, 126.19, 121.51, 119.34, 78.74, 53.68, 42.93, 41.80, 27.60, 24.50, 23.24, 19.04. ESI-HRMS [M+Na]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">30</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>Na: 590.1309, found: 590.1314.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.14" view="all">
                           <ce:label>4.1.1.14</ce:label>
                           <ce:section-title id="sectitle0185">2,3-Difluoro-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B14</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">The title compound was obtained starting from <ce:bold>3</ce:bold> (0.20 mmol, 68.7 mg) and 2,3-difluoro-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>6n</ce:bold>, 0.24 mmol, 63.0 mg). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (93.7 mg, 82.3% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.55 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.45 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.63 (dd, <ce:italic>J</ce:italic> = 8.8, 1.7 Hz, 1H), 7.49–7.43 (m, 1H), 7.33–7.24 (m, 4H), 7.22–7.14 (m, 2H), 4.95–4.86 (m, 1H), 4.69–4.61 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9 Hz, 1H), 1.73–1.64 (m, 1H), 1.61–1.53 (m, 1H), 1.47–1.33 (m, 5H), 1.28 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.92, 165.38, 162.07, 149.52, 144.64, 136.07, 135.86, 128.69, 127.16, 126.41, 124.85, 121.48, 119.70, 118.33, 118.22, 112.61, 111.57, 76.09, 48.95, 38.17, 37.19, 22.88, 19.88, 18.45, 14.29.<ce:sup loc="post">19</ce:sup>F NMR (565 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> −137.42 (d, <ce:italic>J</ce:italic> = 21.4 Hz), −157.76 (d, <ce:italic>J</ce:italic> = 21.4 Hz). ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">29</ce:inf>H<ce:inf loc="post">30</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 570.1691, found: 570.1696.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0190">Synthesis of <ce:bold>B15</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.2.1" view="all">
                           <ce:label>4.1.2.1</ce:label>
                           <ce:section-title id="sectitle0195">Methyl (R)-3-methyl-4-(pentan-2-yloxy)benzoate (<ce:bold>8a</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">DEAD (0.695 mL, 4.41 mmol) was added dropwise to a stirred solution of P(Ph)<ce:inf loc="post">3</ce:inf> (1.16 g, 4.41 mmol) in anhydrous THF at 0 °C. When the reaction mixture became colourless, methyl 4-hydroxy-3-methylbenzoate (489 mg, 2.94 mmol) was added at 0 °C and stirred for 10 min. Subsequently, (<ce:italic>S</ce:italic>)-pentan-2-ol (0.32 mL, 2.94 mmol) was added at 0 °C and stirred for another 10 min. After the reaction mixture was stirred at room temperature for about 20 h, the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (100 mL) and was washed with distilled water (100 mL) for three times. The organic phases were combined, dried over Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, and evaporated under reduced pressure. The crude compound was purified by silica gel column chromatography (PE/EA = 10/1, v/v) to give <ce:bold>8a</ce:bold> (270 mg, 38.9% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 7.75 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.72 (s, 1H), 7.01 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 4.59–4.48 (m, 1H), 3.77 (s, 3H), 2.12 (s, 3H), 1.72–1.59 (m, 1H), 1.57–1.49 (m, 1H), 1.45–1.30 (m, 2H), 1.22 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.86 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 237.1, found: 237.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.2" view="all">
                           <ce:label>4.1.2.2</ce:label>
                           <ce:section-title id="sectitle0200">(R)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9a</ce:bold>)</ce:section-title>
                           <ce:para id="p0215" view="all">To a solution of <ce:bold>8a</ce:bold> (160 mg, 0.677 mmol) in methanol (5 mL) was added 1 M NaOH (5 mL, 5.00 mmol). The resulting mixture was stirred at 50 °C for 12 h. Upon cooling the methanol was removed under vacuum, and the residue was acidified to pH = 2 or below with HCl (1 M). Then the solution was extracted with ethyl acetate (20 mL × 3) and the combined organic solvents were dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 15/1, v/v) to give <ce:bold>9a</ce:bold> (130 mg, 86.4% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.92 (dd, <ce:italic>J</ce:italic> = 8.6, 2.1 Hz, 1H), 7.89 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 4.53–4.43 (m, 1H), 2.22 (s, 3H), 1.82–1.72 (m, 1H), 1.64–1.56 (m, 1H), 1.52–1.38 (m, 2H), 1.32 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.94 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 221.1, found: 221.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.3" view="all">
                           <ce:label>4.1.2.3</ce:label>
                           <ce:section-title id="sectitle0205">(R)-3-methyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>10a</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">Thionyl chloride (10 mL, 1378 mmol) was added to <ce:bold>9a</ce:bold> (111 mg, 0.50 mmol) and stirred for 3 h under reflux condition. After cooling to room temperature, the thionyl chloride was evaporated under reduced pressure to obtain a yellow oil (<ce:bold>10a</ce:bold>), which was used directly for the following synthesis.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.4" view="all">
                           <ce:label>4.1.2.4</ce:label>
                           <ce:section-title id="sectitle0210">3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-(((R)-pentan-2-yl)oxy)benzamide (<ce:bold>B15</ce:bold>)</ce:section-title>
                           <ce:para id="p0225" view="all">Compound <ce:bold>B15</ce:bold> was prepared in a similar manner as described for compounds <ce:bold>B1–B14</ce:bold>, starting from <ce:bold>3</ce:bold> (68.7 mg, 0.20 mmol) and <ce:bold>10a</ce:bold> (57.8 mg, 0.24 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (40.2 mg, 36.7% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.24 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.48 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.83–7.68 (m, 4H), 7.34–7.16 (m, 5H), 7.06 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 4.95–4.86 (m, 1H), 4.61–4.52 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 2.18 (s, 3H), 1.71–1.63 (m, 1H), 1.60–1.52 (m, 1H), 1.49–1.31 (m, 5H), 1.25 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.47, 165.25, 164.36, 158.68, 148.68, 144.13, 136.24, 135.17, 130.14, 128.19, 127.23, 126.66, 126.23, 125.89, 125.82, 120.76, 119.70, 112.41, 111.64, 73.06, 48.45, 37.98, 36.64, 22.39, 19.53, 18.05, 16.20, 13.90. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 548.2036, found: 548.2041.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0215">Synthesis of <ce:bold>B16</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0220">Methyl (S)-3-methyl-4-(pentan-2-yloxy)benzoate (<ce:bold>8b</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Compound <ce:bold>8b</ce:bold> was prepared in a similar manner as described for compound <ce:bold>8a</ce:bold>, starting from <ce:bold>7a</ce:bold> (489 mg, 2.94 mmol) and (R)-pentan-2-ol (0.32 mL, 2.94 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 10/1, v/v) to afford the desired product as colorless oil (444 mg, 64.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.85 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 7.82 (s, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 4.52–4.36 (m, 1H), 3.87 (s, 3H), 2.21 (s, 3H), 1.80–1.70 (m, 1H), 1.65–1.53 (m, 1H), 1.52–1.37 (m, 2H), 1.31 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.93 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 237.1, found: 237.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0225">(S)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9b</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">Compound <ce:bold>9b</ce:bold> was prepared in a similar manner as described for compound <ce:bold>9a</ce:bold>, starting from <ce:bold>8b</ce:bold> (472 mg, 2.00 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using dichloromethane/methanol eluent (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 15/1, v/v) to afford the desired product as colorless oil (444 mg, 100.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.02 (dd, <ce:italic>J</ce:italic> = 8.6, 2.1 Hz, 1H), 7.99 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.93 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 4.63–4.53 (m, 1H), 2.32 (s, 3H), 1.90–1.80 (m, 1H), 1.72–1.64 (m, 1H), 1.60–1.46 (m, 2H), 1.42 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.93 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 221.1, found: 221.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0230">(S)-3-methyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>10b</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">Compound <ce:bold>10b</ce:bold> was prepared in a similar manner as described for compound <ce:bold>10a</ce:bold>, starting from <ce:bold>9b</ce:bold> (111 mg, 0.50 mmol).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.4" view="all">
                           <ce:label>4.1.3.4</ce:label>
                           <ce:section-title id="sectitle0235">3-Methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol -6-yl)-4-(((R)-pentan-2-yl)oxy)benzamide (<ce:bold>B16</ce:bold>)</ce:section-title>
                           <ce:para id="p0245" view="all">Compound <ce:bold>B16</ce:bold> was prepared in a similar manner as described for compounds <ce:bold>B1–B14</ce:bold>, starting from <ce:bold>3</ce:bold> (68.7 mg, 0.20 mmol) and <ce:bold>10b</ce:bold> (57.8 mg, 0.24 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (67.8 mg, 62.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.25 (s, 1H), 8.80 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.47 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 7.84–7.66 (m, 4H), 7.33–7.16 (m, 5H), 7.05 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 4.95–4.86 (m, 1H), 4.61–4.52 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 2.18 (s, 3H), 1.71–1.61 (m, 1H), 1.60–1.52 (m, 1H), 1.46–1.31 (m, 5H), 1.25 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.49, 165.27, 164.38, 158.69, 148.69, 144.13, 136.23, 135.17, 130.14, 128.20, 127.24, 126.67, 126.24, 125.89, 125.80, 120.76, 119.72, 112.42, 111.64, 73.06, 48.46, 37.98, 36.63, 22.39, 19.53, 18.05, 16.21, 13.90. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">34</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 548.2036, found: 548.2041.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0240">Synthesis of <ce:bold>B17</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.4.1" view="all">
                           <ce:label>4.1.4.1</ce:label>
                           <ce:section-title id="sectitle0245">2,3-Dimethyl-4-(pentan-2-yloxy)benzoic acid (<ce:bold>9c</ce:bold>)</ce:section-title>
                           <ce:para id="p0250" view="all">Compound <ce:bold>8c</ce:bold> was synthesized following the synthetic procedure of compounds <ce:bold>5a-5n</ce:bold> and the crude product was obtained. Subsequently, NaOH (1 M) water solution (3 mL, 3.00 mmol) and CH<ce:inf loc="post">3</ce:inf>OH (3 mL) were added and stirred for 1 h. Then the methanol was removed under vacuum, and the residue was acidified to pH = 2 or below with HCl (1 M). Then the solution was extracted with ethyl acetate (20 mL × 3) and the combined organic solvents were dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 15/1, v/v) to give <ce:bold>9c</ce:bold> (white solid, two steps 51.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.40 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.54–4.41 (m, 1H), 2.40 (s, 3H), 2.07 (s, 3H), 1.70–1.59 (m, 1H), 1.56–1.48 (m, 1H), 1.45–1.27 (m, 2H), 1.20 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.86 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 235.1, found: 235.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.2" view="all">
                           <ce:label>4.1.4.2</ce:label>
                           <ce:section-title id="sectitle0250">2,3-Dimethyl-4-(pentan-2-yloxy)benzoyl chloride (<ce:bold>10c</ce:bold>)</ce:section-title>
                           <ce:para id="p0255" view="all">Compound <ce:bold>10c</ce:bold> was prepared in a similar manner as described for compound <ce:bold>10a</ce:bold>, starting from <ce:bold>9c</ce:bold> (118 mg, 0.50 mmol).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.3" view="all">
                           <ce:label>4.1.4.3</ce:label>
                           <ce:section-title id="sectitle0255">2,3-Dimethyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio)benzo[d] thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B17</ce:bold>)</ce:section-title>
                           <ce:para id="p0260" view="all">Compound <ce:bold>B17</ce:bold> was prepared in a similar manner as described for compounds <ce:bold>B1–B14</ce:bold>, starting from <ce:bold>3</ce:bold> (68.7 mg, 0.20 mmol) and <ce:bold>10c</ce:bold> (61.1 mg, 0.24 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (67.3 mg, 60.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>
                              <ce:italic>) δ</ce:italic> 10.40 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 8.50 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.33–7.15 (m, 6H), 6.88 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 4.95–4.85 (m, 1H), 4.55–4.45 (m, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 4.13 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 2.25 (s, 3H), 2.10 (s, 3H), 1.70–1.61 (m, 1H), 1.60–1.51 (m, 1H), 1.46–1.33 (m, 5H), 1.22 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 168.53, 165.45, 164.31, 156.41, 148.65, 144.15, 136.38, 135.40, 135.32, 130.07, 128.21, 126.68, 125.93, 125.64, 120.89, 118.93, 111.53, 109.80, 73.18, 48.45, 38.09, 36.69, 22.40, 19.63, 18.13, 16.66, 13.94, 11.78. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S<ce:inf loc="post">2</ce:inf>: 562.2193, found: 562.2190.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0260">General procedures for the synthesis of <ce:bold>B18–B26</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.5.1" view="all">
                           <ce:label>4.1.5.1</ce:label>
                           <ce:section-title id="sectitle0265">2, 4-dihydroxy-3-methylbenzaldehyde (<ce:bold>16</ce:bold>)</ce:section-title>
                           <ce:para id="p0265" view="all">DMF (6.2 mL, 80.56 mmol) and POCl<ce:inf loc="post">3</ce:inf> (8.1 mL, 88.61 mmol) were mixed and added to a stirred solution of 2-methylbenzene-1,3-diol (<ce:bold>15</ce:bold>, 5.0 g, 0.806 mmol) in ethyl acetate (100 mL) at room temperature. Then water (5 mL) was added to the mixture and stirred for about 2 h. The reaction mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (PE/EA = 5/1, v/v) to give <ce:bold>16</ce:bold> (white solid, 79.9% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.56 (s, 1H), 10.74 (s, 1H), 9.65 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.4, 3.8 Hz, 1H), 6.51 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 1.93 (s, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 151.1, found: 151.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.2" view="all">
                           <ce:label>4.1.5.2</ce:label>
                           <ce:section-title id="sectitle0270">General procedures for the synthesis of compounds <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0270" view="all">To a stirred solution of <ce:bold>16</ce:bold> (152 mg, 1.0 mmol) in DMF (10 mL) were added bromoalkane (302 mg, 2.0 mmol, 2-bromopentane for <ce:bold>17a</ce:bold>; 274 mg, 2.0 mmol, 1-bromo-2-methyl-propan for <ce:bold>17b</ce:bold>; 246 mg, 2.0 mmol, 2-bromopropane for <ce:bold>17c</ce:bold>)、K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (553 mg, 4.0 mmol) and KI (16.6 mg, 0.1 mmol). The mixture was stirred at 80 °C for about 6 h. After cooling and filtration on Celite, the solvent was removed under reduced pressure to obtain an oily residue, which was purified by flash column chromatography on silica (PE/EA = 10/1, v/v) to give <ce:bold>17a-17c</ce:bold>.</ce:para>
                           <ce:section id="sec4.1.5.2.1" view="all">
                              <ce:label>4.1.5.2.1</ce:label>
                              <ce:section-title id="sectitle0275">2-Hydroxy-3-methyl-4-(pentan-2-yloxy) benzaldehyde (<ce:bold>17a</ce:bold>)</ce:section-title>
                              <ce:para id="p0275" view="all">Reddish oil, 60.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.40 (s, 1H), 9.76 (s, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.74 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.65–4.56 (m, 1H), 1.95 (s, 3H), 1.70–1.59 (m, 1H), 1.58–1.48 (m, 1H), 1.47–1.27 (m, 2H), 1.23 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.86 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 221.1, found: 221.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.2.2" view="all">
                              <ce:label>4.1.5.2.2</ce:label>
                              <ce:section-title id="sectitle0280">2-Hydroxy-4-isobutoxy-3-methylbenzaldehyde (<ce:bold>17b</ce:bold>)</ce:section-title>
                              <ce:para id="p0280" view="all">Colorless oil, 75.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.37 (s, 1H), 9.79 (s, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.72 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.86 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.11–2.02 (m, 1H), 2.00 (s, 3H), 0.98 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 6H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 209.1, found: 209.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.2.3" view="all">
                              <ce:label>4.1.5.2.3</ce:label>
                              <ce:section-title id="sectitle0285">4-Isopropoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>17c</ce:bold>)</ce:section-title>
                              <ce:para id="p0285" view="all">Colorless oil, 60.4% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.39 (s, 1H), 9.78 (s, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.85–4.67 (m, 1H), 1.96 (s, 3H), 1.28 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 6H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 195.1, found:195.1.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.5.3" view="all">
                           <ce:label>4.1.5.3</ce:label>
                           <ce:section-title id="sectitle0290">General procedures for the synthesis of compounds <ce:bold>18a</ce:bold>-<ce:bold>18d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0290" view="all">To a solution of <ce:bold>16</ce:bold> or <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold> (1.0 mmol) in DMF (5 mL) were added CH<ce:inf loc="post">3</ce:inf>I (124 mL, 2.0 mmol for <ce:bold>18a</ce:bold>-<ce:bold>18c</ce:bold>, 248 mL, 4.0 mmol for <ce:bold>18d</ce:bold>) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (690 mg, 5.0 mmol). The mixture was stirred at 40 °C. for about 6 h. After cooling and filtration on Celite, the mixture was extracted with ethyl acetate (20 mL × 3) and the combined organic solvents were washed with water (20 mL). Then the organic phase was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compounds were purified by silica gel column chromatography (PE/EA = 7/1, v/v) to give <ce:bold>18a</ce:bold>-<ce:bold>18d.</ce:bold>
                           </ce:para>
                           <ce:section id="sec4.1.5.3.1" view="all">
                              <ce:label>4.1.5.3.1</ce:label>
                              <ce:section-title id="sectitle0295">2-Methoxy-3-methyl-4-(pentan-2-yloxy) benzaldehyde (<ce:bold>18a</ce:bold>)</ce:section-title>
                              <ce:para id="p0295" view="all">Yellow oil, 97.2% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.21 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.71 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.54–4.42 (m, 1H), 3.85 (s, 3H), 2.14 (s, 3H), 1.82–1.70 (m, 1H), 1.64–1.55 (m, 1H), 1.54–1.36 (m, 2H), 1.32 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.94 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 237.3, found: 237.2.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.3.2" view="all">
                              <ce:label>4.1.5.3.2</ce:label>
                              <ce:section-title id="sectitle0300">4-Isobutoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>18b</ce:bold>)</ce:section-title>
                              <ce:para id="p0300" view="all">Colorless oil, 93.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.21 (s, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.70 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.85 (s, 3H), 3.79 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.17 (s, 3H), 2.17–2.06 (m, 1H), 1.06 (s, 3H), 1.04 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 223.1, found: 223.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.3.3" view="all">
                              <ce:label>4.1.5.3.3</ce:label>
                              <ce:section-title id="sectitle0305">4-Isopropoxy-2-methoxy-3-methylbenzaldehyde (<ce:bold>18c</ce:bold>)</ce:section-title>
                              <ce:para id="p0305" view="all">Colorless oil, yield 90.0%, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.08 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.78–4.65 (m, 1H), 3.78 (s, 3H), 2.04 (s, 3H), 1.28 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 6H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 209.1, found: 209.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.3.4" view="all">
                              <ce:label>4.1.5.3.4</ce:label>
                              <ce:section-title id="sectitle0310">2,4-Dimethoxy-3-methylbenzaldehyde (<ce:bold>18d</ce:bold>)</ce:section-title>
                              <ce:para id="p0310" view="all">White solid, 85.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.05 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.91 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 2.03 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 181.1, found:181.1.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.5.4" view="all">
                           <ce:label>4.1.5.4</ce:label>
                           <ce:section-title id="sectitle0315">General procedures for the synthesis of compounds <ce:bold>19a</ce:bold>-<ce:bold>19d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0315" view="all">To a solution of <ce:bold>18a</ce:bold>-<ce:bold>18d</ce:bold> (1.0 mmol) in t-BuOH (8 mL) and 2-methyl-2-butene (4 mL, 47.6 mmol) were added NaClO<ce:inf loc="post">2</ce:inf> (543 mg, 6.0 mmol) and NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>·2H<ce:inf loc="post">2</ce:inf>O (468 mg, 3.0 mmol) buffer solution (pH = 4.5, 8 mL) at 0 °C. Then the mixture was stirred at room temperature for about 1 h. The solution was extracted with ethyl acetate (20 mL × 3) and the organic layer was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compounds were purified by silica gel column chromatography (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 10/1, v/v) to give <ce:bold>19a</ce:bold>-<ce:bold>19d</ce:bold>.</ce:para>
                           <ce:section id="sec4.1.5.4.1" view="all">
                              <ce:label>4.1.5.4.1</ce:label>
                              <ce:section-title id="sectitle0320">2-Methoxy-3-methyl-4-(pentan-2-yloxy) benzoic acid (<ce:bold>19a</ce:bold>)</ce:section-title>
                              <ce:para id="p0320" view="all">White solid, 63.1% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.40 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 4.55–4.42 (m, 1H), 3.66 (s, 3H), 2.01 (s, 3H), 1.69–1.58 (m, 1H), 1.56–1.48 (m, 1H), 1.44–1.29 (m, 2H), 1.21 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.86 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 251.1, found: 251.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.4.2" view="all">
                              <ce:label>4.1.5.4.2</ce:label>
                              <ce:section-title id="sectitle0325">4-Isobutoxy-2-methoxy-3-methylbenzoic acid (<ce:bold>19b</ce:bold>)</ce:section-title>
                              <ce:para id="p0325" view="all">White solid, 83.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.39 (s, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.76 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.66 (s, 3H), 2.04 (s, 3H), 2.04–1.95 (m, 1H), 0.96 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 6H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 237.1, found: 237.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.4.3" view="all">
                              <ce:label>4.1.5.4.3</ce:label>
                              <ce:section-title id="sectitle0330">4-Isopropoxy-2-methoxy-3-methylbenzoic acid (<ce:bold>19c</ce:bold>)</ce:section-title>
                              <ce:para id="p0330" view="all">White solid, 80.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.39 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.71–4.58 (m, 1H), 3.67 (s, 3H), 2.02 (s, 3H), 1.27 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 6H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 223.1, found: 223.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.4.4" view="all">
                              <ce:label>4.1.5.4.4</ce:label>
                              <ce:section-title id="sectitle0335">2,4-Dimethoxy-3-methylbenzoic acid (<ce:bold>19d</ce:bold>)</ce:section-title>
                              <ce:para id="p0335" view="all">White solid, 79.6% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.41 (s, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 3.80 (s, 3H), 3.66 (s, 3H), 2.02 (s, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 195.1, found: 195.1.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.5.5" view="all">
                           <ce:label>4.1.5.5</ce:label>
                           <ce:section-title id="sectitle0340">General procedures for the synthesis of <ce:bold>20a</ce:bold>-<ce:bold>20d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0340" view="all">To a solution of <ce:bold>19a-19d</ce:bold> (0.51 mmol) in 5 mL anhydrous CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> were added SOCl<ce:inf loc="post">2</ce:inf> (607 mg, 5.1 mmol) and DMF (1 drop) at 0 °C. The mixture was stirred at room temperature for 15 min. Then the solution was concentrated <ce:italic>in vacuo</ce:italic> giving <ce:bold>20a-20d</ce:bold>, which were used directly for the following synthesis.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.6" view="all">
                           <ce:label>4.1.5.6</ce:label>
                           <ce:section-title id="sectitle0345">General procedures for the synthesis of <ce:bold>12b</ce:bold>-<ce:bold>12d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0345" view="all">2-Chloroacetyl chloride (169 mg, 1.5 mmol) was added dropwise to a mixture of (<ce:italic>S</ce:italic>)-1-(4-methoxyphenyl)ethan-1-amine derivatives (1.0 mmol) and potassium carbonate (414 mg, 3.0 mmol) in 5 mL of dioxane originally at 0 °C with stirring. Then the resulting mixture was warmed to ambient temperature (25 °C) and stirred for 6 h. After removal of dioxane solvents under reduced pressure, water was added and extracted with ethyl acetate (20 mL × 3). The organic layer was combined and dried with sodium sulfate. The solution was evaporated to give the crude product, which was purified by silica gel column chromatography (PE/EA = 15/1, v/v) to obtain <ce:bold>12b</ce:bold>-<ce:bold>12d</ce:bold>.</ce:para>
                           <ce:section id="sec4.1.5.6.1" view="all">
                              <ce:label>4.1.5.6.1</ce:label>
                              <ce:section-title id="sectitle0350">(S)-2-chloro-N-(1-(4-methoxyphenyl)ethyl)acetamide (<ce:bold>12b</ce:bold>)</ce:section-title>
                              <ce:para id="p0350" view="all">White solid, 27.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.59 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.24 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 4.92–4.82 (m, 1H), 4.06 (s, 2H), 3.73 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 6.5 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 228.1, 230.1, found: 228.1, 230.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.6.2" view="all">
                              <ce:label>4.1.5.6.2</ce:label>
                              <ce:section-title id="sectitle0355">(S)-2-chloro-N-(1-(3-methoxyphenyl)ethyl)acetamide (<ce:bold>12c</ce:bold>)</ce:section-title>
                              <ce:para id="p0355" view="all">White solid, 35.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.61 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.20 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 6.79–6.75 (m, 1H), 4.89–4.79 (m, 1H), 4.04 (s, 2H), 3.71 (s, 3H), 1.32 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 228.1, 230.1, found: 228.1, 230.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.6.3" view="all">
                              <ce:label>4.1.5.6.3</ce:label>
                              <ce:section-title id="sectitle0360">(S)-2-chloro-N-(1-(2-methoxyphenyl)ethyl)acetamide (<ce:bold>12d</ce:bold>)</ce:section-title>
                              <ce:para id="p0360" view="all">White solid, 79.7% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.55 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.25–7.15 (m, 2H), 6.94 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.88 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 5.20–5.08 (m, 1H), 4.05 (s, 2H), 3.77 (s, 3H), 1.25 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 228.1, 230.1, found: 228.1, 230.1.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.5.7" view="all">
                           <ce:label>4.1.5.7</ce:label>
                           <ce:section-title id="sectitle0365">General procedures for the synthesis of <ce:bold>13b</ce:bold>-<ce:bold>13d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0365" view="all">To a solution of <ce:bold>12b</ce:bold>-<ce:bold>12d</ce:bold> (1.0 mmol) in anhydrous dichloromethane (10 mL) was added boron tribromide (17% in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, 1.25 g, 5.0 mmol) at 0 °C. Water (10 mL) was added after the reaction was stirred for 3 h. Then the mixture was stirred for another 30 min before the extraction with dichloromethane (10 mL × 3). The organic layer was combined and dried with sodium sulfate. The solvent was evaporated to give the crude product, which was purified by silica gel column chromatography (PE/EA = 10/1, v/v) to give <ce:bold>13b</ce:bold>-<ce:bold>13d</ce:bold>.</ce:para>
                           <ce:section id="sec4.1.5.7.1" view="all">
                              <ce:label>4.1.5.7.1</ce:label>
                              <ce:section-title id="sectitle0370">(S)-2-chloro-N-(1-(4-hydroxyphenyl)ethyl)acetamide (<ce:bold>13b</ce:bold>)</ce:section-title>
                              <ce:para id="p0370" view="all">White solid, 85.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 9.29 (s, 1H), 8.50 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.09 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 6.68 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 4.80 (quint, 1H), 4.02 (s, 2H), 1.31 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 214.1, 216.1, found:214.1, 216.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.7.2" view="all">
                              <ce:label>4.1.5.7.2</ce:label>
                              <ce:section-title id="sectitle0375">(S)-2-chloro-N-(1-(3-hydroxyphenyl)ethyl)acetamide (<ce:bold>13c</ce:bold>)</ce:section-title>
                              <ce:para id="p0375" view="all">White solid, 85.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 9.34 (s, 1H), 8.57 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.07 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 6.72–6.65 (m, 2H), 6.59 (dd, <ce:italic>J</ce:italic> = 8.0, 1.5 Hz, 1H), 4.83–4.73 (m, 1H), 4.02 (s, 2H), 1.30 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 214.1, 216.1, found:214.1, 216.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.7.3" view="all">
                              <ce:label>4.1.5.7.3</ce:label>
                              <ce:section-title id="sectitle0380">(S)-2-chloro-N-(1-(2-hydroxyphenyl)ethyl)acetamide (<ce:bold>13d</ce:bold>)</ce:section-title>
                              <ce:para id="p0380" view="all">White solid, 82.8% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 9.55 (s, 1H), 8.50 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.13 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.04–6.98 (m, 1H), 6.77–6.69 (m, 2H), 5.14–5.06 (m, 1H), 4.05 (s, 2H), 1.27 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 214.1, 216.1, found:214.1, 216.1.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.5.8" view="all">
                           <ce:label>4.1.5.8</ce:label>
                           <ce:section-title id="sectitle0385">General procedures for the synthesis of <ce:bold>14a</ce:bold>-<ce:bold>14e</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0385" view="all">The syntheses of the compounds <ce:bold>14a</ce:bold>-<ce:bold>14e</ce:bold> starting from 6-aminobenzothiazole-2-thiol (91.1 mg, 0.50 mmol) and <ce:bold>12b</ce:bold>-<ce:bold>12c</ce:bold> or <ce:bold>13b</ce:bold>-<ce:bold>13d</ce:bold> (0.50 mmol) were previously reported in ref. 32 (syntheses of <ce:bold>13a</ce:bold>-<ce:bold>g</ce:bold>) and the obtained intermediates were directly used for the following step.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.9" view="all">
                           <ce:label>4.1.5.9</ce:label>
                           <ce:section-title id="sectitle0390">General procedures for the synthesis of <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0390" view="all">The syntheses of the products <ce:bold>B18</ce:bold>–<ce:bold>B26</ce:bold> from <ce:bold>20a</ce:bold>-<ce:bold>20d</ce:bold> (0.24 mmol) and <ce:bold>3</ce:bold> (68.7 mg, 0.20 mmol) or <ce:bold>14a</ce:bold>-<ce:bold>14e</ce:bold> (0.20 mmol) were similar to the previously reported method published in ref. 32. The residues were purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired products.</ce:para>
                           <ce:section id="sec4.1.5.9.1" view="all">
                              <ce:label>4.1.5.9.1</ce:label>
                              <ce:section-title id="sectitle0395">2-Methoxy-3-methyl-N-(2-((2-oxo-2-(((S)-1-phenylethyl)amino)ethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-4-(pentan-2-yloxy)benzamide (<ce:bold>B18</ce:bold>)</ce:section-title>
                              <ce:para id="p0395" view="all">White solid, 50.7% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.30 (s, 1H), 8.79 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.49 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.46 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.33–7.16 (m, 5H), 6.87 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.95–4.85 (m, 1H), 4.55–4.47 (m, 1H), 4.16 (d, <ce:italic>J</ce:italic> = 14.9, 1H), 4.12 (d, <ce:italic>J</ce:italic> = 14.9, 1H) 3.71 (s, 3H), 2.08 (s, 3H), 1.70–1.61 (m, 1H), 1.59–1.50 (m, 1H), 1.47–1.27 (m, 5H), 1.23 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.88 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.52, 164.85, 164.45, 158.76, 156.74, 148.73, 144.10, 136.03, 135.33, 128.21, 127.79, 126.68, 125.88, 121.27, 120.92, 119.80, 119.16, 111.82, 108.25, 73.41, 61.48, 48.47, 37.99, 36.60, 22.37, 19.55, 18.07, 13.89, 8.99. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S<ce:inf loc="post">2</ce:inf>: 578.2142, found: 578.2144.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.2" view="all">
                              <ce:label>4.1.5.9.2</ce:label>
                              <ce:section-title id="sectitle0400">2-Methoxy-N-(2-((2-(((S)-1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo [d]thiazol-6-yl)-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B19</ce:bold>)</ce:section-title>
                              <ce:para id="p0400" view="all">White solid, 30.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.12 (s, 1H), 8.62 (s, 1H), 8.06 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.42 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.15 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 6.82 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.77 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 5.04 (quint, 1H), 4.51 (sext, 1H), 3.92 (brd, <ce:italic>J</ce:italic> = 14.7, 2H), 3.90 (s, 3H), 3.77 (s, 3H), 2.23 (s, 3H), 1.85–1.72 (m, 1H), 1.58–1.48 (m, 1H), 1.48–1.32 (m, 2H),1.44 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 3H), 1.36 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 3H), 0.98 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 167.20, 165.02, 163.65, 160.72, 158.70, 157.44, 148.76, 136.64, 135.96, 135.05, 130.12, 127.14, 121.24, 120.58, 118.95, 117.66, 113.90, 112.13, 108.79, 74.11, 61.76, 55.25, 48.80, 38.60, 36.36, 21.82, 19.77, 18.71, 14.08, 9.25. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">38</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 608.2247, found: 608.2243.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.3" view="all">
                              <ce:label>4.1.5.9.3</ce:label>
                              <ce:section-title id="sectitle0405">2-Methoxy-N-(2-((2-(((S)-1-(3-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B20</ce:bold>)</ce:section-title>
                              <ce:para id="p0405" view="all">White solid, 20.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.09 (s, 1H), 8.58 (s, 1H), 8.02 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.70 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.39 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.15 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 6.82–6.70 (m, 4H), 5.04 (quint, 1H), 4.51 (sext, 1H), 3.93 (s, 2H), 3.87 (s, 3H), 3.69 (s, 3H), 2.20 (s, 3H), 1.83–1.71 (m, 1H), 1.67–1.53 (m, 3H), 1.42 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 3H), 1.33 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.95 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.72, 164.58, 163.02, 160.10, 159.14, 156.82, 148.08, 144.03, 136.00, 135.38, 129.50, 129.01, 120.66, 119.95, 118.35, 117.56, 117.08, 111.91, 111.49, 111.20, 108.19, 73.50, 61.12, 54.48, 48.75, 37.98, 35.75, 21.39, 19.14, 18.07, 13.43, 8.60. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">37</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 608.2247, found: 608.2241.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.4" view="all">
                              <ce:label>4.1.5.9.4</ce:label>
                              <ce:section-title id="sectitle0410">N-(2-((2-(((S)-1-(4-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B21</ce:bold>)</ce:section-title>
                              <ce:para id="p0410" view="all">White solid, 18.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.05 (s, 1H), 8.14 (d, <ce:italic>J</ce:italic> = 1.8 Hz 1H), 8.05 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.35 (dd, <ce:italic>J</ce:italic> = 8.6, 1.8 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 6.86–6.73 (m, 4H), 6.41 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 4.96 (quint, 1H), 4.50 (sext, 1H), 3.92 (brd, <ce:italic>J</ce:italic> = 14.7, 2H), 3.89 (s, 3H), 2.20 (s, 3H), 1.84–1.72 (m, 1H), 1.70–1.56 (m, 1H), 1.55–1.44 (m, 2H), 1.42 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 3H), 1.34 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.96 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.53, 164.90, 164.87, 160.98, 157.76, 155.49, 149.78, 136.40, 134.59, 133.75, 130.31, 126.93, 121.67, 121.58, 120.64, 116.99, 115.45, 115.16, 108.73, 74.14, 61.77, 48.70, 38.58, 36.15, 20.71, 19.76, 18.70, 14.07, 9.27. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 594.2091, found: 594.2089.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.5" view="all">
                              <ce:label>4.1.5.9.5</ce:label>
                              <ce:section-title id="sectitle0415">N-(2-((2-(((S)-1-(3-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B22</ce:bold>)</ce:section-title>
                              <ce:para id="p0415" view="all">White solid, 25.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.09 (s, 1H), 8.38 (s, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.38 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.02 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 6.72 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 6.60 (d, <ce:italic>J</ce:italic> = 12.7 Hz, 2H), 4.96 (quint, 1H), 4.50 (sext, 1H), 3.92 (brd, <ce:italic>J</ce:italic> = 14.7, 2H), 3.88 (s, 3H), 2.21 (s, 3H), 1.86–1.74 (m, 1H), 1.63–1.55 (m, 1H), 1.55–1.43 (m, 2H), 1.42 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 3H), 0.97 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 165.10, 162.88, 161.86, 158.57, 155.32, 154.22, 146.74, 142.03, 134.17, 133.05, 127.76, 127.24, 119.13, 118.35, 117.86, 115.52, 115.13, 112.32, 111.00, 106.58, 71.93, 59.57, 47.14, 36.30, 33.97, 19.25, 17.57, 16.51, 11.88, 7.06. ESI-HRMS [M + H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 594.2091, found: 594.2094.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.6" view="all">
                              <ce:label>4.1.5.9.6</ce:label>
                              <ce:section-title id="sectitle0420">N-(2-((2-(((S)-1-(2-hydroxyphenyl)ethyl)amino)-2-oxoethyl)thio)benzo[d] thiazol-6-yl)-2-methoxy-3-methyl-4-(pentan-2-yloxy)benzamide (<ce:bold>B23</ce:bold>)</ce:section-title>
                              <ce:para id="p0420" view="all">White solid, 22.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.13 (s, 1H), 8.77 (s, 1H), 8.60 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 8.27 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.45 (dd, <ce:italic>J</ce:italic> = 8.7, 2.1 Hz, 1H), 7.21–7.14 (m, 2H), 6.93 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 6.85 (td, <ce:italic>J</ce:italic> = 7.5, 1.0 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 5.26 (quint, 1H), 4.50 (sext, 1H), 4.00 (d, <ce:italic>J</ce:italic> = 15.1 Hz, 1H), 3.90 (s, 3H), 3.86 (d, <ce:italic>J</ce:italic> = 15.0 Hz, 1H), 2.23 (s, 3H), 1.86–1.76 (m, 1H), 1.66–1.58 (m, 1H), 1.56–1.42 (m, 2H), 1.54 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 3H), 1.36 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 3H), 0.98 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 168.83, 164.06, 163.09, 160.14, 156.84, 154.36, 148.01, 136.04, 135.43, 129.51, 128.45, 127.82, 125.20, 120.60, 119.97, 119.65, 118.56, 117.54, 117.00, 111.64, 108.19, 73.52, 61.13, 43.21, 37.98, 35.34, 19.14, 18.63, 18.07, 13.43, 8.61. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 594.2091, found: 594.2093.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.7" view="all">
                              <ce:label>4.1.5.9.7</ce:label>
                              <ce:section-title id="sectitle0425">(S)-4-isobutoxy-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2- oxoethyl)thio) benzo [d]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B24</ce:bold>)</ce:section-title>
                              <ce:para id="p0425" view="all">White solid, 70.4% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.31 (s, 1H), 8.69 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.52 (s, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.50 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.86 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.82 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 4.87 (quint, 1H), 4.13 (brd, <ce:italic>J</ce:italic> = 14.8 Hz, 2H), 3.81 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.74 (s, 3H), 3.70 (s, 3H), 2.14 (s, 3H), 2.10–2.01 (m, 1H), 1.34 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H), 1.00 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.51, 164.45, 162.99, 160.86, 158.09, 156.59, 148.13, 136.02, 135.33, 134.44, 129.69, 126.50, 120.63, 119.29, 118.33, 117.41, 113.29, 111.51, 107.10, 74.16, 61.18, 54.61, 48.17, 35.75, 27.73, 21.17, 18.62, 8.41. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">35</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 594.2091, found: 594.2091.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.8" view="all">
                              <ce:label>4.1.5.9.8</ce:label>
                              <ce:section-title id="sectitle0430">(S)-4-isopropoxy-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)- 2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B25</ce:bold>)</ce:section-title>
                              <ce:para id="p0430" view="all">White solid, 68.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.31 (s, 1H), 8.69 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 8.52 (s, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.88 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 4.86 (quint, 1H), 4.71–4.58 (m, 1H), 4.14 (brd, <ce:italic>J</ce:italic> = 14.8 Hz, 2H), 3.70 (d, <ce:italic>J</ce:italic> = 12.2 Hz, 6H), 2.09 (s, 3H), 1.33 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H), 1.28 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.53, 164.43, 163.01, 159.86, 158.09, 156.84, 148.12, 136.02, 135.34, 134.44, 129.47, 126.50, 120.63, 120.02, 118.32, 117.18, 113.29, 111.51, 108.35, 69.96, 61.11, 54.61, 48.17, 35.75, 21.49, 21.17, 8.61. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">33</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 580.1934, found: 580.1937.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.5.9.9" view="all">
                              <ce:label>4.1.5.9.9</ce:label>
                              <ce:section-title id="sectitle0435">(S)-2,4-dimethoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B26</ce:bold>)</ce:section-title>
                              <ce:para id="p0435" view="all">White solid, 65.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.30 (s, 1H), 8.67 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 8.49 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.49 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 6.86 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 4.84 (quint, 1H), 4.12 (brd, <ce:italic>J</ce:italic> = 14.8 Hz, 2H), 3.81 (s, 3H), 3.70 (s, 3H), 3.67 (s, 3H), 2.08 (s, 3H), 1.31 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.52, 164.49, 162.94, 161.28, 158.09, 156.56, 148.15, 136.02, 135.28, 134.43, 129.75, 126.50, 120.64, 119.23, 118.33, 117.74, 113.29, 111.53, 106.31, 61.20, 55.23, 54.62, 48.17, 35.75, 21.17, 8.40. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 552.1621, found: 552.1617.</ce:para>
                           </ce:section>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0440">General procedures for the synthesis of <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.6.1" view="all">
                           <ce:label>4.1.6.1</ce:label>
                           <ce:section-title id="sectitle0445">4-(benzyloxy)-2-hydroxy-3-methylbenzaldehyde (<ce:bold>22</ce:bold>)</ce:section-title>
                           <ce:para id="p0440" view="all">To a solution of <ce:bold>21</ce:bold> (3.0 g, 19.72 mmol) in acetonitrile were added benzyl bromide (2.58 mL, 21.69 mmol), KI (327 mg, 1.972 mmol) and potassium carbonate (6.0 g, 43.38 mmol). The mixture was stirred at reflux for about 6 h and the completion of the reaction was monitored by TLC and LC-MS. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (100 mL), and washed with water and brine. Then the organic phase dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (PE/EA = 15/1, v/v) to give <ce:bold>22</ce:bold> as a white solid (4.0 g，88.2% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.35 (s, 1H), 9.78 (s, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.43 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 7.38 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.31 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 6.82 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 5.23 (s, 2H), 2.02 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 231.1, found:231.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.2" view="all">
                           <ce:label>4.1.6.2</ce:label>
                           <ce:section-title id="sectitle0450">4-(benzyloxy)-2-methoxy-3-methylbenzaldehyde (<ce:bold>23</ce:bold>)</ce:section-title>
                           <ce:para id="p0445" view="all">To a solution of <ce:bold>22</ce:bold> (3.0 g, 13.03 mmol) in anhydrous DMF were added CH<ce:inf loc="post">3</ce:inf>I (3.25 mL, 52.12 mmol) and potassium carbonate (3.96 g, 28.67 mmol). The mixture was stirred at 40 °C for about 3 h and the completion of the reaction was monitored by TLC and LC-MS. After cooling to room temperature, water was added and the mixture was extracted with ethyl acetate (100 mL) twice. The combined organic layers were washed with brine and the organic phase was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. Finally, the crude compound was purified by silica gel column chromatography (PE/EA = 10/1, v/v) to give <ce:bold>23</ce:bold> as a white solid (3.3 g, 98.9% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.08 (s, 1H), 7.61 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.44 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.38 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.31 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 7.02 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 5.21 (s, 2H), 3.78 (s, 3H), 2.11 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 257.1, found:257.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.3" view="all">
                           <ce:label>4.1.6.3</ce:label>
                           <ce:section-title id="sectitle0455">4-(benzyloxy)-2-methoxy-3-methylbenzoic acid (<ce:bold>24</ce:bold>)</ce:section-title>
                           <ce:para id="p0450" view="all">To a solution of <ce:bold>23</ce:bold> (3.0 g, 11.7 mmol) in t-BuOH (30 mL) and 2-methyl-2-butene (10 mL) were added NaClO<ce:inf loc="post">2</ce:inf> (1.59 g, 17.55 mmol) and NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>·2H<ce:inf loc="post">2</ce:inf>O (4.2 g, 35.1 mmol) buffer solution (pH = 4.5, 35 mL) at 0 °C. Then the mixture was stirred at room temperature for about 1 h. The solution was extracted with ethyl acetate (100 mL × 3) and the organic layer was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 10/1, v/v) to give <ce:bold>24</ce:bold> (3.18 g, 100% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.04 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.44 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.38 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 7.31 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 6.88 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 5.15 (s, 2H), 3.67 (s, 3H), 2.08 (s, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 271.3, found: 271.3.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.4" view="all">
                           <ce:label>4.1.6.4</ce:label>
                           <ce:section-title id="sectitle0460">4-Hydroxy-2-methoxy-3-methylbenzoic acid (<ce:bold>25</ce:bold>)</ce:section-title>
                           <ce:para id="p0455" view="all">A solution of compound <ce:bold>24</ce:bold> (3.0 g, 11.03 mmol) in methanol (30 mL) was hydrogenated in the presence of 10% Pd/C (300 mg) and H<ce:inf loc="post">2</ce:inf> (balloon pressure) at room temperature for 1 h. The mixture was then filtered through a Celite pad and the filtrate was concentrated <ce:italic>in vacuo</ce:italic> to give <ce:bold>25,</ce:bold> which was used directly for the following synthesis. ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 181.1, found: 181.2.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.5" view="all">
                           <ce:label>4.1.6.5</ce:label>
                           <ce:section-title id="sectitle0465">Methyl 4-hydroxy-2-methoxy-3-methylbenzoate (<ce:bold>26</ce:bold>)</ce:section-title>
                           <ce:para id="p0460" view="all">SOCl<ce:inf loc="post">2</ce:inf> (796 μL, 10.98 mmol) was slowly added to a solution of <ce:bold>26</ce:bold> (2.0 g, 10.98 mmol) in dry methanol (25 mL) and the solution was stirred at rt for 5 h. After removing the solvent under reduced pressure, the residue was dissolved in ethyl acetate (50 mL), washed with water and brine. Then the organic phase was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (PE/EA = 6/1, v/v) to give <ce:bold>26</ce:bold> as a white solid（2.1 g，98.0% yield）. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.24 (s, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.62 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 3.72 (s, 3H), 3.65 (s, 3H), 2.00 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 197.1, found:197.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.6" view="all">
                           <ce:label>4.1.6.6</ce:label>
                           <ce:section-title id="sectitle0470">General procedures for the synthesis of <ce:bold>27a</ce:bold>-<ce:bold>27d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0465" view="all">To a solution of <ce:bold>26</ce:bold> (196 mg, 1.0 mmol) in anhydrous DMF were added different alkyl halides (278 mg, 2.0 mmol, 1-bromo-2-methoxyethane for <ce:bold>27a</ce:bold>, 340 mg, 2.0 mmol, 1-(2-chloroethyl)pyrrolidine hydrochloride for <ce:bold>27b</ce:bold>, 288 mg, 2.0 mmol, 2-chloro-N,N-dimethylethan-1-amine hydrochloride for <ce:bold>27c</ce:bold>, 372 mg, 2.0 mmol, 4-(2-chloroethyl)morpholine hydrochloride for <ce:bold>27d</ce:bold>), KI (16.6 mg, 0.1 mmol) and potassium carbonate (414 mg, 3.0 mmol). The mixture was stirred at 100 °C for about 2 h and the completion of the reaction was monitored by TLC and LC-MS. After cooling to room temperature, water was added. The mixture was extracted with ethyl acetate (20 mL) twice. The combined organic layers were washed with brine and the organic phase was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude compound was purified by silica gel column chromatography (PE/EA = 10/1, v/v) to give <ce:bold>27a-27d</ce:bold>.</ce:para>
                           <ce:section id="sec4.1.6.6.1" view="all">
                              <ce:label>4.1.6.6.1</ce:label>
                              <ce:section-title id="sectitle0475">Methyl 2-methoxy-4-(2-methoxyethoxy)-3-methylbenzoate (<ce:bold>27a</ce:bold>)</ce:section-title>
                              <ce:para id="p0470" view="all">Brown oil, 93.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 7.59 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.14–4.10 (m, 2H), 3.75 (s, 3H), 3.68–3.63 (m, 5H), 3.29 (s, 3H), 2.04 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 255.1, found:255.2.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.6.6.2" view="all">
                              <ce:label>4.1.6.6.2</ce:label>
                              <ce:section-title id="sectitle0480">Methyl 2-methoxy-3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)benzoate (<ce:bold>27b</ce:bold>)</ce:section-title>
                              <ce:para id="p0475" view="all">Brown oil, 41.9% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.72 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.63 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.15 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.87 (s, 3H), 3.79 (s, 3H), 2.94 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 2.70–2.62 (m, 4H), 2.15 (s, 3H), 1.84–1.76 (m, 4H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 294.2, found:294.2.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.6.6.3" view="all">
                              <ce:label>4.1.6.6.3</ce:label>
                              <ce:section-title id="sectitle0485">Methyl 4-(2-(dimethylamino)ethoxy)-2-methoxy-3-methylbenzoate (<ce:bold>27c</ce:bold>)</ce:section-title>
                              <ce:para id="p0480" view="all">Brown oil, 84.3% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 7.59 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.07 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 3.75 (s, 3H), 3.66 (s, 3H), 2.63 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 2.20 (s, 6H), 2.03 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 268.2, found:268.1.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.6.6.4" view="all">
                              <ce:label>4.1.6.6.4</ce:label>
                              <ce:section-title id="sectitle0490">Methyl 2-methoxy-3-methyl-4-(2-morpholinoethoxy)benzoate (<ce:bold>27d</ce:bold>)</ce:section-title>
                              <ce:para id="p0485" view="all">Brown oil, 90.5% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 4.12 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 3.75 (s, 3H), 3.66 (s, 3H), 3.57–3.51 (m, 4H), 2.70 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 2.03 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 310.1, found:310.2.</ce:para>
                           </ce:section>
                        </ce:section>
                        <ce:section id="sec4.1.6.7" view="all">
                           <ce:label>4.1.6.7</ce:label>
                           <ce:section-title id="sectitle0495">2-Methoxy-4-(2-methoxyethoxy)-3-methylbenzoic acid (<ce:bold>28a</ce:bold>)</ce:section-title>
                           <ce:para id="p0490" view="all">Compound <ce:bold>28a</ce:bold> was prepared in a similar manner as described for compound <ce:bold>9c</ce:bold>, starting from 2<ce:bold>7a</ce:bold> (139 mg, 0.545 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using dichloromethane/methanol eluent (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 10/1, v/v) to afford the desired product as white solid (131 mg, 100.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 7.59 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.15–4.07 (m, 2H), 3.67–3.63 (m, 5H), 3.29 (s, 3H), 2.04 (s, 3H). ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 239.1, found:239.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.8" view="all">
                           <ce:label>4.1.6.8</ce:label>
                           <ce:section-title id="sectitle0500">General procedures for the synthesis of <ce:bold>28b</ce:bold>-<ce:bold>28d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0495" view="all">6 M HCl aqueous solution (5 mL) was added to <ce:bold>27b</ce:bold>-<ce:bold>27d</ce:bold> (0.545 mmol) and the solution was stirred at 80 °C for about 6 h. After solvent evaporation under reduced pressure, the residue was used for the following synthesis.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.9" view="all">
                           <ce:label>4.1.6.9</ce:label>
                           <ce:section-title id="sectitle0505">General procedures for the synthesis of <ce:bold>29a</ce:bold>-<ce:bold>29d</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0500" view="all">Compounds <ce:bold>29a</ce:bold>-<ce:bold>29d</ce:bold> were prepared in a similar manner as described for compounds <ce:bold>20a</ce:bold>-<ce:bold>20d</ce:bold>, starting from <ce:bold>28a</ce:bold>-<ce:bold>28d</ce:bold> (0.50 mmol).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.10" view="all">
                           <ce:label>4.1.6.10</ce:label>
                           <ce:section-title id="sectitle0510">General procedures for the synthesis of <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0505" view="all">The syntheses of the products <ce:bold>B27</ce:bold>–<ce:bold>B30</ce:bold> from <ce:bold>29a</ce:bold>-<ce:bold>29d</ce:bold> (0.24 mmol) and <ce:bold>14a</ce:bold> (74.7 mg, 0.20 mmol) were similar to the previously reported method published in ref. 32. The residues were purified by flash column chromatography on silica gel (200–300 mesh) using dichloromethane/methanol eluent (DCM/CH<ce:inf loc="post">3</ce:inf>OH = 10/1, v/v) to afford the desired products.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.11" view="all">
                           <ce:label>4.1.6.10.1</ce:label>
                           <ce:section-title id="sectitle0515">(S)-2-methoxy-4-(2-methoxyethoxy)-N-(2-((2-((1-(4-methoxyphenyl)ethyl) amino)-2-oxoethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B27</ce:bold>)</ce:section-title>
                           <ce:para id="p0510" view="all">White solid, 35.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.33 (s, 1H), 8.69 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.53 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.77 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.69 (dd, <ce:italic>J</ce:italic> = 8.9, 2.0 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 4.93–4.83 (m, 1H), 4.20–4.13 (m, 4H), 3.75 (s, 3H), 3.73–3.69 (m, 5H), 3.34 (s, 3H), 2.14 (s, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.77, 165.27, 164.91, 159.88, 158.53, 157.08, 149.27, 136.60, 136.55, 135.86, 128.34, 127.59, 122.52, 121.44, 119.77, 119.65, 114.05, 112.32, 107.88, 70.86, 68.35, 62.01, 58.85, 55.51, 48.31, 37.23, 22.84, 9.41. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">33</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">6</ce:inf>S<ce:inf loc="post">2</ce:inf>: 596.1884, found: 596.1887.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.12" view="all">
                           <ce:label>4.1.6.10.2</ce:label>
                           <ce:section-title id="sectitle0520">(S)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)thio) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)benzamide (<ce:bold>B28</ce:bold>)</ce:section-title>
                           <ce:para id="p0515" view="all">White solid, 35.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.94 (s, 1H), 8.49 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 7.98 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.33 (dd, <ce:italic>J</ce:italic> = 8.7, 1.9 Hz, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.74 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 6.67 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 4.99–4.90 (m, 1H), 4.34 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.85 (brd, <ce:italic>J</ce:italic> = 14.7, 2H), 3.80 (s, 3H), 3.67 (s, 3H), 3.24 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.08–3.02 (m, 4H), 2.16 (s, 3H), 2.00–1.92 (m, 4H), 1.34 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 167.17, 165.20, 163.34, 160.21, 158.70, 157.28, 148.83, 136.64, 135.78, 135.05, 130.54, 127.13, 121.27, 119.84, 119.17, 118.98, 113.91, 112.21, 107.82, 65.67, 61.93, 55.26, 54.60, 54.24, 48.81, 36.37, 23.40, 21.82, 9.32. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">38</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 635.2356, found: 635.2358.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.13" view="all">
                           <ce:label>4.1.6.10.3</ce:label>
                           <ce:section-title id="sectitle0525">(S)-4-(2-(dimethylamino)ethoxy)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl) ethyl)amino)-2-oxoethyl)thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B29</ce:bold>)</ce:section-title>
                           <ce:para id="p0520" view="all">White solid, 32.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.34 (s, 1H), 8.72 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.52 (s, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.69 (dd, <ce:italic>J</ce:italic> = 8.8, 1.5 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.91 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 4.92–4.82 (m, 1H), 4.20–4.07 (m, 4H), 3.74 (s, 3H), 3.71 (s, 3H), 2.72 (t, <ce:italic>J</ce:italic> = 5.5 Hz, 2H), 2.27 (s, 6H), 2.13 (s, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.86, 165.29, 164.95, 159.88, 158.50, 157.06, 149.27, 136.53, 135.86, 128.42, 127.58, 122.26, 121.46, 119.68, 114.03, 112.36, 107.71, 67.08, 62.02, 57.96, 55.49, 48.34, 45.96, 37.18, 22.81, 9.40. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">31</ce:inf>H<ce:inf loc="post">36</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: 609.2200, found: 609.2195.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.14" view="all">
                           <ce:label>4.1.6.10.4</ce:label>
                           <ce:section-title id="sectitle0530">(S)-2-methoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) thio)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methyl-4-(2-morpholinoethoxy)benzamide (<ce:bold>B30</ce:bold>)</ce:section-title>
                           <ce:para id="p0525" view="all">White solid, 30.0% yield, <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.93 (s, 1H), 8.49 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 7.99 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.33 (dd, <ce:italic>J</ce:italic> = 8.7, 2.1 Hz, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.75 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 6.67 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 4.99–4.90 (m, 1H), 4.37 (t, <ce:italic>J</ce:italic> = 4.5 Hz, 2H), 3.92–3.82 (m, 6H), 3.81 (s, 3H), 3.67 (s, 3H), 3.14 (t, <ce:italic>J</ce:italic> = 4.5 Hz, 2H), 2.99–2.87 (m, 4H), 2.15 (s, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 167.19, 165.26, 163.29, 158.71, 157.31, 148.86, 136.65, 135.73, 135.04, 130.58, 127.14, 121.29, 119.85, 118.98, 113.91, 112.23, 107.84, 65.24, 61.95, 57.09, 55.26, 53.40, 48.82, 36.36, 21.81, 9.31. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">33</ce:inf>H<ce:inf loc="post">38</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">6</ce:inf>S<ce:inf loc="post">2</ce:inf>: 651.2306, found: 651.2315.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0535">General procedures for the synthesis of <ce:bold>B31</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.7.1" view="all">
                           <ce:label>4.1.7.1</ce:label>
                           <ce:section-title id="sectitle0540">Tert-butyl (S)-(2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)carbamate (<ce:bold>31</ce:bold>)</ce:section-title>
                           <ce:para id="p0530" view="all">To a solution of (<ce:italic>tert</ce:italic>-butoxycarbonyl)glycine (1.0 g, 5.7 mmol) in anhydrous THF (30 mL) were added HATU (2.17 g, 5.7 mmol) and HOAT (776 mg, 5.7 mmol) at 0 °C for 15 min. Then (S)-1-(4-methoxyphenyl)ethan-1-amine (860 mg, 5.7 mmol) and DIPEA (3.0 mL, 17.1 mmol) were added. The mixture was stirred at room temperature for about 8 h and the completion of the reaction was monitored by TLC. Then the aqueous layer was extracted with ethyl acetate (100 mL) twice, and the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE/EA = 10/1, v/v) to afford intermediate <ce:bold>31</ce:bold> (colorless oil, 92.8% yield). <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.22 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.85 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 6.58 (s, 1H), 5.33 (s, 1H), 5.12–5.00 (m, 1H), 3.78 (s, 3H), 3.75 (d, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 1.46 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H), 1.43 (s, 9H). ESI-MS: calcd for [M + Na]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 331.2, found:331.0.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.2" view="all">
                           <ce:label>4.1.7.2</ce:label>
                           <ce:section-title id="sectitle0545">(S)-2-amino-N-(1-(4-methoxyphenyl)ethyl)acetamide (<ce:bold>32</ce:bold>)</ce:section-title>
                           <ce:para id="p0535" view="all">To a solution of <ce:bold>31</ce:bold> (1.0 g, 3.25 mmol) in anhydrous CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (15 mL) was added trifluoroacetic acid (1.5 mL) at 0 °C and stirred for 3 h. After removal of the solvents under reduced pressure, saturated sodium bicarbonate solution and CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> were added. The organic layer was washed with brine, dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic> to give the crude product, which was used directly for the next step. ESI-MS: calcd for [M + H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 209.1, found:209.2.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.3" view="all">
                           <ce:label>4.1.7.3</ce:label>
                           <ce:section-title id="sectitle0550">(S)–N-(1-(4-methoxyphenyl)ethyl)-2-((6-nitrobenzo[<ce:italic>d</ce:italic>]thiazol-2-yl)amino) acetamide (<ce:bold>33</ce:bold>)</ce:section-title>
                           <ce:para id="p0540" view="all">To a solution of 2-chloro-6-nitrobenzo [<ce:italic>d</ce:italic>]thiazole (114 mg, 0.53 mmol) in n-butyl alcohol (5 mL) were added <ce:bold>32</ce:bold> (110 mg, 0.53 mmol) and Et<ce:inf loc="post">3</ce:inf>N (242 μL, 1.75 mmol) at 0 °C. The mixture was stirred at reflux for about 3 h and the completion of the reaction was monitored by TLC. Reducing temperature led to a precipitation of compound <ce:bold>33</ce:bold>, which was filtered and dried (yellow solid, 73.5% yield). <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.97 (t, <ce:italic>J</ce:italic> = 5.5 Hz, 1H), 8.72 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 8.51 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 8.13 (dd, <ce:italic>J</ce:italic> = 8.9, 2.4 Hz, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.26 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.87 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 4.96–4.88 (m, 1H), 4.14 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 2H), 3.72 (s, 3H), 1.36 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 3H). ESI-MS: calcd for [M + H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 387.1, found:387.2.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.4" view="all">
                           <ce:label>4.1.7.4</ce:label>
                           <ce:section-title id="sectitle0555">(S)-2-((6-aminobenzo[<ce:italic>d</ce:italic>]thiazol-2-yl)amino)-N-(1-(4-methoxyphenyl)ethyl) acetamide (<ce:bold>34</ce:bold>)</ce:section-title>
                           <ce:para id="p0545" view="all">To a solution of <ce:bold>33</ce:bold> (150 mg, 0.39 mmol) in CH<ce:inf loc="post">3</ce:inf>CH<ce:inf loc="post">2</ce:inf>OH/H<ce:inf loc="post">2</ce:inf>O (10 mL/5 mL) were added Fe powder (109 mg, 1.95 mmol) and NH<ce:inf loc="post">4</ce:inf>Cl (104 mg, 1.95 mmol) at room temperature. The mixture was stirred at reflux for about 3 h and the completion of the reaction was monitored by TLC. After cooling and filtration on Celite, the mixture was extracted with ethyl acetate (20 mL × 3) and the combined organic solvents were washed with water. The organic layer was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic> to give the crude product, which was used directly for the next step. ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 357.1, found:357.2.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.7.5" view="all">
                           <ce:label>4.1.7.5</ce:label>
                           <ce:section-title id="sectitle0560">(S)-2,4-dimethoxy-N-(2-((2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl) amino)benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B31</ce:bold>)</ce:section-title>
                           <ce:para id="p0550" view="all">The synthesis of the product <ce:bold>B31</ce:bold> from <ce:bold>20d</ce:bold> (51.5 mg, 0.24 mmol) and <ce:bold>34</ce:bold> (71.3 mg, 0.20 mmol) was similar to the previously reported method published in ref. 32. The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (80.2 mg, 75.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.10 (s, 1H), 8.43 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 8.19 (dd, <ce:italic>J</ce:italic> = 11.1, 3.8 Hz, 2H), 7.52 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.48 (dd, <ce:italic>J</ce:italic> = 8.7, 1.9 Hz, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.26 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 4.96–4.86 (m, 1H), 4.03 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 3.85 (s, 3H), 3.74 (s, 3H), 3.72 (s, 3H), 2.12 (s, 3H), 1.35 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 167.58, 165.40, 164.10, 159.82, 157.82, 156.27, 148.32, 136.24, 132.97, 130.73, 127.77, 126.98, 121.86, 118.70, 118.11, 117.62, 113.38, 112.08, 106.15, 61.34, 55.71, 54.88, 47.10, 46.45, 22.29, 8.71. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">5</ce:inf>S: 535.2010, found: 535.2010.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title id="sectitle0565">General procedures for the synthesis of <ce:bold>B32</ce:bold>
                        </ce:section-title>
                        <ce:section id="sec4.1.8.1" view="all">
                           <ce:label>4.1.8.1</ce:label>
                           <ce:section-title id="sectitle0570">N-(2-chlorobenzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-2,4-dimethoxy-3-methylbenzamide (<ce:bold>36</ce:bold>)</ce:section-title>
                           <ce:para id="p0555" view="all">Compounds <ce:bold>36</ce:bold> was prepared in a similar manner as described for compound <ce:bold>B1–B14</ce:bold>, starting from 2-chlorobenzo [<ce:italic>d</ce:italic>]thiazol-6-amine (<ce:bold>35</ce:bold>, 923 mg, 5.0 mmol) and <ce:bold>20d</ce:bold> (1.29 g, 6.0 mmol). The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 10/1, v/v) to afford the desired product (1.27 g, 70.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.12 (s, 1H), 8.68 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 8.06 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.36 (dd, <ce:italic>J</ce:italic> = 8.8, 2.2 Hz, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 2.21 (s, 3H). ESI-MS: calcd for [M+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 363.0, found:363.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.2" view="all">
                           <ce:label>4.1.8.2</ce:label>
                           <ce:section-title id="sectitle0575">N-(2-chlorobenzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-2,4-dimethoxy-3-methylbenzamide (<ce:bold>37</ce:bold>)</ce:section-title>
                           <ce:para id="p0560" view="all">To a solution of <ce:bold>36</ce:bold> (363 mg, 1.0 mmol) in anhydrous THF were added ethyl 2-hydroxyacetate (257 mg, 1.2 mmol) and NaH (60 mg, 1.5 mmol, 60% dispersion in mineral oil). The mixture was stirred at reflux for about 2 h and the completion of the reaction was monitored by TLC. After adding water (2 mL), the mixture was extracted with ethyl acetate (10 mL × 3). Then the organic phase was dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic> to give the crude product, which was purified by silica gel column chromatography (PE/EA = 6/1, v/v) to obtain compound <ce:bold>37</ce:bold> as colorless oil (278 mg, 64.6% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.98 (s, 1H), 8.44 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 8.07 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.35 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H), 6.81 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 5.08 (s, 2H), 4.29 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 2.21 (s, 3H), 1.30 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H). ESI-MS: calcd for [M + H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 431.1, found: 431.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.3" view="all">
                           <ce:label>4.1.8.3</ce:label>
                           <ce:section-title id="sectitle0580">2-((6-(2,4-dimethoxy-3-methylbenzamido)benzo[<ce:italic>d</ce:italic>]thiazol-2-yl)oxy)acetic acid (<ce:bold>38</ce:bold>)</ce:section-title>
                           <ce:para id="p0565" view="all">The compound <ce:bold>37</ce:bold> (270 mg, 0.63 mmol) was stirred in NaOH (1 M) water solution (5 mL) and THF (5 mL) for 5 min. Then the THF was removed under vacuum, and the residue was acidified to pH = 2 or below with HCl (1 M). Then the solution was extracted with ethyl acetate (20 mL × 3) and the combined organic solvents were dried with sodium sulfate and concentrated <ce:italic>in vacuo</ce:italic>. The crude product was used directly for next step. ESI-MS: calcd for [M − H]<ce:sup loc="post">-</ce:sup> 
                              <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 401.1, found:401.1.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.4" view="all">
                           <ce:label>4.1.8.4</ce:label>
                           <ce:section-title id="sectitle0585">(S)-2,4-dimethoxy-N-(2-(2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethoxy) benzo[<ce:italic>d</ce:italic>]thiazol-6-yl)-3-methylbenzamide (<ce:bold>B32</ce:bold>)</ce:section-title>
                           <ce:para id="p0570" view="all">The synthesis of the product <ce:bold>B32</ce:bold> from <ce:bold>11b</ce:bold> (30.2 mg, 0.20 mmol) and <ce:bold>38</ce:bold> (80.5 mg, 0.20 mmol) was similar to the previously reported method published in ref. 32. The residue was purified by flash column chromatography on silica gel (200–300 mesh) using petroleum ether/ethyl acetate eluent (PE/EA = 3/1, v/v) to afford the desired product as white solid (93.1 mg, 87.0% yield). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.26 (s, 1H), 8.63 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 8.41 (s, 1H), 7.66–7.58 (m, 2H), 7.53 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.26 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.86 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 5.05–4.86 (m, 3H), 3.85 (s, 3H), 3.74 (s, 3H), 3.72 (s, 3H), 2.12 (s, 3H), 1.37 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (150 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 170.73, 165.00, 164.49, 159.93, 157.88, 156.31, 144.34, 135.97, 135.28, 131.82, 127.77, 127.00, 121.82, 120.33, 118.77, 113.40, 112.52, 106.17, 68.75, 61.38, 55.73, 54.88, 46.96, 22.06, 8.70. ESI-HRMS [M+H]<ce:sup loc="post">+</ce:sup> calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">6</ce:inf>S: 536.1850, found: 536.1846.</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0590">Biological evaluation</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0595">Luciferase report assay</ce:section-title>
                        <ce:section id="sec4.2.1.1" view="all">
                           <ce:label>4.2.1.1</ce:label>
                           <ce:section-title id="sectitle0600">Cell lines culture</ce:section-title>
                           <ce:para id="p0575" view="all">HepG2 cells were stably transfected with corresponding STAT-responsive firefly luciferase reporter plasmid and were cultured in a-MEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). HEK-293 cells were stably transfected with NF-κB-responsive firefly luciferase reporter plasmid and were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). All the cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.2.1.2" view="all">
                           <ce:label>4.2.1.2</ce:label>
                           <ce:section-title id="sectitle0605">Luciferase report assay</ce:section-title>
                           <ce:para id="p0580" view="all">Procedure was similar to the published method in ref.32.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0610">Cell viability assays</ce:section-title>
                        <ce:section id="sec4.2.2.1" view="all">
                           <ce:label>4.2.2.1</ce:label>
                           <ce:section-title id="sectitle0615">Cell lines culture</ce:section-title>
                           <ce:para id="p0585" view="all">MDA-MB-468 cell lines were cultured in DMEM/F-12 supplemented with 10% (v/v) fetal bovine serum, 50 mg/mL penicillin/streptomycin. HEL cell lines were maintained in high glucose DMEM replenished with 10% fetal bovine serum and 50 mg/mL penicillin/streptomycin. All the cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.2.2.2" view="all">
                           <ce:label>4.2.2.2</ce:label>
                           <ce:section-title id="sectitle0620">MTT assay</ce:section-title>
                           <ce:para id="p0590" view="all">Procedure was similar to published methods in ref. [<ce:cross-ref id="crosref0385" refid="bib49">49</ce:cross-ref>].</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0625">Western blotting</ce:section-title>
                        <ce:para id="p0595" view="all">Cells were collected and lysed using pre-heated 2% SDS by vortexing for 2–3 s at maximum speed, followed by boiling for 30 min. Protein concentrations were determined by BCA assay (Beyotime, P0011). Proteins were subjected to SDS-PAGE, transferred to nitrocellulose membranes (Immobilon-P, Millipore) and blocked for 1 h at room temperature with 3% milk in 1xTris-buffered saline Tween-20 (TBST) (25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4, supplemented with 0.1% Tween-20).</ce:para>
                        <ce:para id="p0600" view="all">Membranes were probed with a 1:1000 dilution of primary antibodies (Cell Signaling Technology) against Phospho-STAT3 (Tyr705), Phospho-STAT3 (Ser727), STAT3, c-Myc, MCL-1, β-actin and GAPDH at 4 °C overnight. After washing the membranes with TBST three times for 30 min, horseradish peroxidase-conjugated anti-rabbit IgG (dilution, 1: 2000) or anti-mouse IgG (dilution, 1: 5000) antibodies were incubated at room temperature for 1 h. The membranes were washed with TBST three times for 30 min, and the antigen-antibody reaction was visualized with an enhanced chemiluminescence assay (Thermo Scientific) or Femto chemiluminescence assay (Thermo Scientific).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0630">In vitro kinases activities test</ce:section-title>
                        <ce:para id="p0605" view="all">For the kinase assay based on the ELISA system, procedure was similar to published methods in ref. [<ce:cross-ref id="crosref0390" refid="bib50">50</ce:cross-ref>] and ref.[<ce:cross-ref id="crosref0395" refid="bib51">51</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title id="sectitle0635">Flow cytometry analysis of apoptotic cells</ce:section-title>
                        <ce:para id="p0610" view="all">Cells were seeded in 12-well plates for overnight and then treated with DMSO or the indicated compounds for 48 h. Then cells were collected and rinsed twice with PBS. After resuspending the cells in 500 μL binding buffer, 5 μL Annexin V-FITC and 5 μL propidium iodide (A211-01, Vazyme) were added and mixed gently. Finally, the mixture was incubated for 15 min at room temperature in dark and detected by a flow cytometer (BD FACs Calibur).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title id="sectitle0640">Cell cycle effect</ce:section-title>
                        <ce:para id="p0615" view="all">Cells were seeded in 12-well plates overnight and then treated with DMSO or the indicated compounds for 48 h. The cells were washed with PBS and fixed in ice-cold 80% ethanol overnight. For analysis, cells were incubated for 30 min at 37 °C with PI (ST512, Beyotime Biotechnology)-containing RNase (B600476-0001, Sangon Biotech) and detected by a flow cytometer (BD FACS CALIBUR).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.7" view="all">
                        <ce:label>4.2.7</ce:label>
                        <ce:section-title id="sectitle0645">Surface plasmon resonance analysis</ce:section-title>
                        <ce:para id="p0620" view="all">Purified STAT3 protein (His-tag 127–722 amino acid, DetaiBio, China) was immobilized on sensor chip CM5 (GE Healthcare) and carried out at 25 °C on Biacore T200 instruments. Approximately 11269.8 RU of STAT3 was amino coupled to a CM5 Chip (according to the manufacturer’s protocol), and another cell being left blank for reference subtraction. HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20, pH 7.4) was used as running buffer. The operating conditions: contact time: 30 s, flow rate: 30 μL/min, dissociation time: 45 s. The regeneration conditions: contact time: 30 s, flow rate: 30 μL/min. The ratio of the association and dissociation rate constants was determined as the affinity (equilibrium constants, <ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf>). The <ce:italic>K</ce:italic>
                           <ce:inf loc="post">D</ce:inf> (equilibrium constant) values were calculated as <ce:italic>k</ce:italic>
                           <ce:inf loc="post">d</ce:inf> (dissociation rate constant)/<ce:italic>k</ce:italic>
                           <ce:inf loc="post">a</ce:inf> (associated rate constant) for each interaction and determined by globally fitting with Biacore T200 evaluation software 2.0 (GE Healthcare).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.8" view="all">
                        <ce:label>4.2.8</ce:label>
                        <ce:section-title id="sectitle0650">Fluorescence polarization assay</ce:section-title>
                        <ce:para id="p0625" view="all">Procedure was similar to the published method in ref. 48. Before adding tested compounds, the 5-FAM-GpYLPQTV-NH2 probe was incubated with STAT3 SH2 domain protein in assay buffer (Hepes 10 mM，pH = 7.5，EDTA 1 mM，NaCl 50 mM，0.1% Nonidet P40) for 30 min at 37 °C. Then, competition experiments were performed using different concentrations of compounds. The binding rate was calculated with the following formula: binding rate (%) = (maximum value - drug treatment value)/(maximum value - minimum value) × 100%.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.9" view="all">
                        <ce:label>4.2.9</ce:label>
                        <ce:section-title id="sectitle0655">Molecular docking</ce:section-title>
                        <ce:para id="p0630" view="all">The X-ray crystal structure of STAT3/DNA complex (PDB code: <ce:inter-ref id="intref0020" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) was used for docking studies applying Schrodinger software package. Firstly, one monomer was deleted and the missing hydrogen atoms were added. Also, the bond order and the correct protonation were prepared using protein preparation wizard model. Then the complex was submitted to a series of restrained minimizations to relieve static clashes using the OPLS-2005 force field. Subsequently, the receptor grid was generated at the centroid of selected residues (Gln644, Glu638) and the size of grid box was 20 Å × 20 Å × 20 Å. After preparing the ligands, molecular docking was carried out using the standard precision (SP) with the default settings. Finally, the pictures were generated using Pymol software.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0660">Declaration of competing interest</ce:section-title>
               <ce:para id="p0635" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0665">Acknowledgement</ce:section-title>
               <ce:para id="p0640" view="all">Financial support was generously provided by the <ce:grant-sponsor id="gs3" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Significant New Drugs Development</ce:grant-sponsor> (<ce:grant-number refid="gs3">2018ZX09711002-003-009</ce:grant-number>), the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (Nos. <ce:grant-number refid="gs2">81973178</ce:grant-number> and <ce:grant-number refid="gs2">U1906212</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0670">Supplementary data</ce:section-title>
                  <ce:para id="p0645" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523421001823/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0675">Supplementary data</ce:section-title>
                  <ce:para id="p0650" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0025" xlink:href="https://doi.org/10.1016/j.ejmech.2021.113333" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2021.113333</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0680">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">T. Bowman, R. Garcia, J. Turkson, et al. STATs in oncogenesis, Oncogene 21 (2000) 2474-2488.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">J.E. Darnell, Jr. Transcription factors as targets for cancer therapy, Nat. Rev. Cancer 2 (2002) 740-749.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>James</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs and gene regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1630</sb:first-page>
                              <sb:last-page>1635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">E. James, Jr. Darnell, STATs and gene regulation, Science 277 (1997) 1630-1635.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Ihle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Witthuhn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.W.</ce:given-name>
                                 <ce:surname>Quelle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signaling through the hematopoietic cytokine receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>369</sb:first-page>
                              <sb:last-page>398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J.N. Ihle, B.A. Witthuhn, F.W. Quelle, K. Yamamoto, O. Silvennoinen, Signaling through the hematopoietic cytokine receptors, Annu. Rev. Immunol. 13 (1997) 369-398.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>van Boxel-Dezaire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16975</sb:first-page>
                              <sb:last-page>16980</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Y. Wang, A.H. van Boxel-Dezaire, H. Cheon, J. Yang, G.R. Stark, STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor, Proc. Natl. Acad. Sci. U.S.A. 110 (2013) 16975-16980.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laundano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45443</sb:first-page>
                              <sb:last-page>45455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">J. Turkson, D. Ryan, J.S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laundano, S. Sebti, A.D. Hamilton, R. Jove, Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, J. Biol. Chem. 276 (2001) 45443-45455.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Alexander</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppressors of cytokine signalling (SOCS) in the immune system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>410</sb:first-page>
                              <sb:last-page>416</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">W. S. Alexander, Suppressors of cytokine signalling (SOCS) in the immune system, Nature Rev. Immunol. 2 (2002) 410-416.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kubo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hanada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yoshimura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppressors of cytokine signaling and immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1169</sb:first-page>
                              <sb:last-page>1176</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">M. Kubo, T. Hanada, A. Yoshimura, Suppressors of cytokine signaling and immunity, Nature Immunol. 4 (2003) 1169-1176.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shuai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of gene-activation pathways by PIAS proteins in the immune system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>593</sb:first-page>
                              <sb:last-page>605</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">K. Shuai, B. Liu, Regulation of gene-activation pathways by PIAS proteins in the immune system, Nature Rev. Immunol. 5 (2005) 593-605.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Validating Stat3 in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">J.E. Darnell, Validating Stat3 in cancer therapy, Nat. Med. 11 (2005) 595-596.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>945</sb:first-page>
                              <sb:last-page>954</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">R. Buettner, L.B. Mora, R. Jove, Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention, Clin. Cancer Res. 8 (2002) 945-954.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT proteins: novel molecular targets for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6613</sb:first-page>
                              <sb:last-page>6626</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">J. Turkson, R. Jove, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene 19 (2000) 6613-6626.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT proteins as novel targets for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>409</sb:first-page>
                              <sb:last-page>422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">J. Turkson, STAT proteins as novel targets for cancer drug discovery, Expert Opin. Ther. Targets 8 (2004) 409-422.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer: new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">H. Yu, R. Jove, The STATs of cancer: new molecular targets come of age, Nat. Rev. Cancer 4 (2004) 97-105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in cancer inflammation and immunity: a leading role for STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: a leading role for STAT3, Nature Rev. Cancer 9 (2009) 798-809.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kujawski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reckamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Armstrong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kowolik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Figlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7455</sb:first-page>
                              <sb:last-page>7464</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">A. Herrmann, M. Kortylewski, M. Kujawski, C. Zhang, K. Reckamp, B. Armstrong, L. Wang, C. Kowolik, J. Deng, R. Figlin, H. Yu, Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells, Cancer Res. 70 (2010) 7455-7464.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of Stat3 in suppressing anti-tumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>228</sb:first-page>
                              <sb:last-page>233</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">M. Kortylewski, H. Yu, Role of Stat3 in suppressing anti-tumor immunity, Curr. Opin. Immunol. 20 (2008) 228-233.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kujawski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pilon-Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mulé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Kerr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1314</sb:first-page>
                              <sb:last-page>1321</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mule, W.G. Kerr, R. Jove, D. Pardoll, H. Yu, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity, Nature Med. 11 (2005) 1314-1321.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat. Rev. Immunol. 7 (2007) 41-51.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kumari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dwarakanath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Bhatt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of interleukin-6 in cancer progression and therapeutic resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumor Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11553</sb:first-page>
                              <sb:last-page>11572</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">N. Kumari, B. Dwarakanath, A. Das, A.N. Bhatt, Role of interleukin-6 in cancer progression and therapeutic resistance, Tumor Biol. 37 (2016) 11553-11572.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gharibi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Babaloo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hosseini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdollahpour-Alitappeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Hashemi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Marofi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nejati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Baradaran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting STAT3 in cancer and autoimmune diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>878</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>173107</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">T. Gharibi, Z. Babaloo, A. Hosseini, M. Abdollahpour-Alitappeh, V. Hashemi, F. Marofi, K. Nejati, B. Baradaran, Targeting STAT3 in cancer and autoimmune diseases. Eur. J. Pharmacol. 878 (2020) 173107.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STAT3 in autophagy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autophagy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>729</sb:first-page>
                              <sb:last-page>739</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">L. You, Z. Wang, H. Li, J. Shou, Z. Jing, J. Xie, X. Sui, H. Pan, W. Han. The role of STAT3 in autophagy, Autophagy 11 (2015) 729-739.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>O’Keefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">D.E. Johnson, R.A. O’Keefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol. 15 (2018) 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Cameron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Dyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Muranjan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Campbell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6661</sb:first-page>
                              <sb:last-page>6670</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">D. R Coleman, Ren, Z. P. K. Mandal, A. G. Cameron, G. A. Dyer, S. Muranjan, M. Campbell, X. Chen, J.S. McMurray, Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor, J. Med. Chem. 48 (2005) 6661−6670.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nikolovska-Coleska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">J. Chen, L. Bai, D. Bernard, Z. Nikolovska-Coleska, C. Gomez, J. Zhang, H. Yi, S. Wang. Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors, ACS Med. Chem. Lett. 2 (2010) 85−89.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>DeAngelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">L. Lin, B. Hutzen, P.K. Li, S. Ball, M. Zuo, S. DeAngelis, E. Foust, M. Sobo, L. Friedman, D. Bhasin, L. Cen, C. Li, J. Lin, A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells, Neoplasia 12 (2010) 39-50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">L. Bai, H. Zhou, R. Xu, Y. Zhao, K. Chinnaswamy, D. McEachern, J. Chen, C.Y. Yang, Z. Liu, M. Wang, L. Liu, H. Jiang, B. Wen, P. Kumar, J.L. Meagher, D. Sun, J.A. Stuckey, S. Wang, A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo, Cancer Cell 36 (2019) 498−511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gelain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meneghetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Villa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription protein 3 (stat3): an update on its direct inhibitors as promising anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5165</sb:first-page>
                              <sb:last-page>5206</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">A. Gelain, M. Mori, F. Meneghetti, S. Villa, Signal transducer and activator of transcription protein 3 (stat3): an update on its direct inhibitors as promising anticancer agents, Curr Med Chem. 26 (2019) 5165-5206.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="bib29a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Rogoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Keates</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Murikipudi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mikule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Leggett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Pardee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of cancer relapse and metastasis by inhibiting cancer stemness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>112</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1839</sb:first-page>
                              <sb:last-page>1844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Y. Li, H.A. Rogoff, S. Keates, Y. Gao, S. Murikipudi, K. Mikule, D. Leggett, W. Li, A.B. Pardee, C.J. Li, Suppression of cancer relapse and metastasis by inhibiting cancer stemness, Proc. Natl. Acad. Sci. U. S. A 112 (2015) 1839-1844.</ce:source-text>
                     <sb:reference id="bib29b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Jonker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Nott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yoshino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ohtsu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Napabucasin versus placebo in refractory advanced colorectal cancer: a randomized phase 3 trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Gastroenterol Hepatol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>263</sb:first-page>
                              <sb:last-page>270</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">D.J. Jonker, L. Nott, T. Yoshino, S. Gill, J. Shapiro, A. Ohtsu, et al., Napabucasin versus placebo in refractory advanced colorectal cancer: a randomized phase 3 trial, Lancet Gastroenterol Hepatol. 3 (2018) 263-270.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-A.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.-Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-Y.</ce:given-name>
                                 <ce:surname>Ryoo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res Treat</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>510</sb:first-page>
                              <sb:last-page>518</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">C. Yoo, J. Kang, H. Y. Lim, J. H. Kim, M.-A. Lee, K.-H. Lee, T.-Y. Kim, B.-Y. Ryoo, Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma, Cancer Res Treat. 2 (2019) 510-518.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="bib31a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.-X.</ce:given-name>
                                 <ce:surname>Di</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti Canc. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>846</sb:first-page>
                              <sb:last-page>853</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">J.-X. Di, H.-Y. Zhang, C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma, Anti Canc. Drugs 8 (2019) 846-853.</ce:source-text>
                     <ce:other-ref id="bib31ab">
                        <ce:label>(b)</ce:label>
                        <ce:textref>ClinicalTrials.gov. <ce:inter-ref id="intref0030" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03195699" xlink:type="simple">https://clinicaltrials.gov/ct2/show/NCT03195699</ce:inter-ref> (accessed 6 January 2021).</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>301</sb:first-page>
                              <sb:last-page>310</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">M. Zhang, W. Zhu, Y. Li, Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening, Eur. J. Med. Chem. 62 (2013) 301−310.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hagiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okuyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sugimura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chiral perturbation factor" approach reveals importance of entropy term in stereocontrol of the 2,4-pentanediol-tethered reaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6593</sb:first-page>
                              <sb:last-page>6598</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">T. Tei, Y. Sato, K. Hagiya, A. Tai, T. Okuyama, T. Sugimura, "Chiral perturbation factor" approach reveals importance of entropy term in stereocontrol of the 2,4-pentanediol-tethered reaction, J. Org. Chem. 67 (2002) 6593−6598.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cruciani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kharazmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Liljefors</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antileishmanial chalconesstatistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4819</sb:first-page>
                              <sb:last-page>4832</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">S.F. Nielsen, S.B. Christensen, G. Cruciani, A. Kharazmi, T. Liljefors, Antileishmanial chalconesstatistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis, J. Med. Chem. 41 (1998) 4819−4832.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Moreau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Couture</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Deniau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Grandclaudon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lebrun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>First total synthesis of cichorine and zinnimidine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Biomol. Chem<ce:italic>.</ce:italic>
                                    </sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2305</sb:first-page>
                              <sb:last-page>2309</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">A. Moreau, A. Couture, E. Deniau, P. Grandclaudon, S. Lebrun, First total synthesis of cichorine and zinnimidine, Org. Biomol. Chem. 3 (2005) 2305−2309.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Guagnano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Spanka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bordas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Douget</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Stamm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brueggen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Jensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Schmid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wartmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Berghausen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Drueckes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zimmerlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bussiere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Porta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7066</sb:first-page>
                              <sb:last-page>7083</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">V. Guagnano, P. Furet, C. Spanka, V. Bordas, M.L. Douget, C. Stamm, J. Brueggen, M.R. Jensen, C. Schnell, H. Schmid, M. Wartmann, J. Berghausen, P. Drueckes, A. Zimmerlin, D. Bussiere, J. Murray, D.G. Porta. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase, J. Med. Chem. 54 (2005) 7066−7083.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Roesel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Guagnano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4451</sb:first-page>
                              <sb:last-page>4454</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">P. Furet, G. Bold, T. Meyer, J. Roesel, V. Guagnano, Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents, J. Med. Chem. 49 (2006) 4451−4454.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Eom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Noh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High-Throughput screening protocol for the coupling reactions of aryl halides using a colorimetric chemosensor for halide ions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1720</sb:first-page>
                              <sb:last-page>1723</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">M.S. Eom, J. Noh, H.S. Kim, S. Yoo, M.S. Han, M.S. Lee, High-Throughput Screening Protocol for the Coupling Reactions of Aryl Halides Using a Colorimetric Chemosensor for Halide Ions, Org. Lett. 18 (2016) 1720−1723.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bhatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Steffen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chergui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Murai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pommier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Pascal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Trombetta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Fronczek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Talele</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5579</sb:first-page>
                              <sb:last-page>5601</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">M.R. Patel, A. Bhatt, J.D. Steffen, A. Chergui, J. Murai, Y. Pommier, J.M. Pascal, L.D. Trombetta, F.R. Fronczek, T.T. Talele, Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors, J. Med. Chem. 57 (2014) 5579−5601.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Bisht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dwivedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Chaturvedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Anand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Misra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dwivedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Sinha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Dwivedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Tripathi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5965</sb:first-page>
                              <sb:last-page>5978</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">S.S. Bisht, N. Dwivedi, V. Chaturvedi, N. Anand, M. Misra, R. Sharma, B. Kumar, R, Dwivedi, S. Singh, S.K. Sinha, V. Gupta, P.R. Mishra, A.K. Dwivedi, R.P. Tripathi, Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols, Eur. J. Med. Chem. 45 (2010) 5965−5978.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bamborough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Barnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Becher</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>GSK6853, a chemical probe for inhibition of the BRPF1 bromodomain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>552</sb:first-page>
                              <sb:last-page>557</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">P. Bamborough, H. A. Barnett, I. Becher, et al. GSK6853, a chemical probe for inhibition of the BRPF1 bromodomain, ACS Med. Chem. Lett. 7 (2016) 552-557.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Bharadwaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Eckols</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kolosov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kasembeli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Adam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Torres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Dobrolecki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dave</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Landis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Creighton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Mancini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1341</sb:first-page>
                              <sb:last-page>1353</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">U. Bharadwaj, T.K. Eckols, M. Kolosov, M.M. Kasembeli, A. Adam, D. Torres, X. Zhang, L.E. Dobrolecki, W. Wei, M.T. Lewis, B. Dave, J.C. Chang, M.D. Landis, C.J. Creighton, M.A. Mancini, D.J. Tweardy, Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer, Oncogene 34 (2015) 1341-1353.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Decker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kovarik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Serine phosphorylation of STATs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2628</sb:first-page>
                              <sb:last-page>2637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">T. Decker, P. Kovarik, Serine phosphorylation of STATs, Oncogene 19 (2000) 2628-2637.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kiuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ichiba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fukada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Narimatsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mizuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hibi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hirano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 is required for the gp130-mediated full activation of the c-myc gene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>189</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>63</sb:first-page>
                              <sb:last-page>73</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">N. Kiuchi, K. Nakajima, M. Ichiba, T. Fukada, M. Narimatsu, K. Mizuno, M. Hibi, T. Hirano, STAT3 is required for the gp130-mediated full activation of the c-myc gene, J. Exp. Med.189 (1999) 63-73.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Puthier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bataille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Amiot</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3945</sb:first-page>
                              <sb:last-page>3950</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">D. Puthier, R. Bataille, M. Amiot, IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway, Eur. J. Immunol. 29 (1999) 3945-3950.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anal. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>330</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>114</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">J. Schust, T. Berg, A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3, Anal Biochem. 330 (2004) 114-118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">J. Schust, B. Sperl, A. Hollis, T.U. Mayer, T. Berg, Stattic: a small-molecule inhibitor of STAT3 activation and dimerization, Chem. Biol. 13 (2006) 1235-1242.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>201</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112428</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">K. Feng, F. Wang, X. Shi, et al. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy, Eur. J. Med. Chem. 201 (2020) 112428.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q. Yu</ce:given-name>
                                 <ce:surname>Angoline</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A selective IL-6/STAT3 signaling pathway inhibitor isolated from Zanthoxylum nitidum</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Phytomedicine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1088</sb:first-page>
                              <sb:last-page>1091</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">J. Liu, Q. Zhang, Y. Ye, W. Li, J. Qiu, J. Liu, R. Zhan, W. Chen, Q. Yu. Angoline: a selective IL-6/STAT3 signaling pathway inhibitor isolated from Zanthoxylum nitidum, Phytomedicine 21 (2014) 1088−1091.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR <ce:sup loc="post">L858R/T790M/C797S</ce:sup>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>869</sb:first-page>
                              <sb:last-page>873</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Q. Li, T. Zhang, S. Li, L. Tong, J. Li, Z. Su, F. Feng, D. Sun, Y. Tong, X. Wang, Z. Zhao, L. Zhu, J. Ding, H. Li, H. Xie, Y. Xu. Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR L858R/T790M/C797S. ACS Med. Chem. Lett. 10 (2019), 869-873.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Saito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Azuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kamio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gemma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunopharmacol. Immunotoxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>464</sb:first-page>
                              <sb:last-page>471</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">Y. Saito, A. Azuma, K. Matsuda, K. Kamio, S. Abe, A. Gemma. Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. Immunopharmacol & Immunotoxicol 38 (2016) 464-471.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>